



## General

### Guideline Title

Guidelines for the management of hemophilia.

### Bibliographic Source(s)

Guidelines for the management of hemophilia. 2nd ed. Montreal (Quebec): World Federation of Hemophilia; 2012. 74 p. [324 references]

### Guideline Status

This is the current release of the guideline.

This guideline updates a previous version: Guidelines for the management of hemophilia. Montreal (Quebec): World Federation of Hemophilia; 2005. 56 p.

## Recommendations

### Major Recommendations

*Note from the National Guideline Clearinghouse (NGC): In addition to the evidence-based "position statements" below, the guidelines working group also identifies recommendations based on expert opinion in the full-text guideline document.*

Levels of evidence (1-5) are defined at the end of the "Major Recommendations" field.

#### General Care and Management of Hemophilia

##### Principles of Care

Acute bleeds should be treated as quickly as possible, preferably within two hours. If in doubt, treat. (Level 4) (Ingram et al., 1979)

To facilitate appropriate management in emergency situations, all patients should carry easily accessible identification indicating the diagnosis, severity of the bleeding disorder, inhibitor status, type of treatment product used, initial dosage for treatment of severe, moderate, and mild bleeding, and contact information of the treating physician/clinic. (Level 5) (Singleton, Kruse-Jarres, & Leissingner, 2010)

Administration of desmopressin (DDAVP) can raise coagulation factor VIII (FVIII) level adequately (three to six times baseline levels) to control bleeding in patients with mild, and possibly moderate, hemophilia A. Testing for DDAVP response in individual patients is appropriate. (Level 3) (Castaman et al., 2009; Franchini, Zaffanello, & Lippi, 2010; Mannucci, 2000)

##### Comprehensive Care

Comprehensive care promotes physical and psychosocial health and quality of life while decreasing morbidity and mortality. (Level 3) (Berntorp et

al., 1995; Kasper et al., 1992; Soucie et al., 2000)

### *Comprehensive Care Team*

The wide-ranging needs of people with hemophilia and their families are best met through the coordinated delivery of comprehensive care by a multidisciplinary team of healthcare professionals, in accordance with accepted protocols that are practical and national treatment guidelines, if available. (Level 5) (Colvin et al., 2008; Evatt, 2006; Evatt et al., 2004)

### *Functions of a Comprehensive Care Program*

To provide or coordinate inpatient (i.e., during hospital stays) and outpatient (clinic and other visits) care and services to patients and their family.

- Patients should be seen by all core team members at least yearly (children every six months) for a complete hematologic, musculoskeletal, and psychosocial assessment and to develop, audit, and refine an individual's comprehensive management plan. Referrals for other services can also be given during these visits. (Level 5) (Canadian Hemophilia Standards Group, 2007; de Moerloose et al., 2012)

### *Fitness and Physical Activity*

Physical activity should be encouraged to promote physical fitness and normal neuromuscular development, with attention paid to muscle strengthening, coordination, general fitness, physical functioning, healthy body weight, and self-esteem. (Level 2) (Gomis et al., 2009)

For patients with significant musculoskeletal dysfunction, weight-bearing activities that promote development and maintenance of good bone density should be encouraged, to the extent their joint health permits. (Level 3) (Iorio et al., 2010)

Target joints can be protected with braces or splints during activity, especially when there is no clotting factor coverage. (Level 4) (Philpott, Houghton, & Luke, 2010; Querol et al., 2002)

### *Prophylactic Factor Replacement Therapy*

Prophylaxis prevents bleeding and joint destruction and should be the goal of therapy to preserve normal musculoskeletal function. (Level 2) (Aronstam et al., 1976; Astermark et al., 1999; Feldman et al., 2006; Fischer et al., 2002; Gringeri et al., 2011; Manco-Johnson et al., 2007)

In patients with repeated bleeding, particularly into target joints, short-term prophylaxis for 4 to 8 weeks can be used to interrupt the bleeding cycle. This may be combined with intensive physiotherapy or synoviorrhesis. (Level 3) (Kavakli et al., 2008; Luchtman-Jones et al., 2006)

### *Administration and Dosing Schedules*

Prophylactic administration of clotting factor concentrates is advisable prior to engaging in activities with higher risk of injury. (Level 4) (Seuser et al., 2007; Luchtman-Jones et al., 2006; Petrini & Seuser, 2009)

### *Home Therapy*

Home therapy allows immediate access to clotting factor and hence optimal early treatment, resulting in decreased pain, dysfunction, and long-term disability and significantly decreased hospital admissions for complications. (Level 3) (Soucie et al., 2001; Teitel et al., 2004)

Home treatment must be supervised closely by the comprehensive care team and should only be initiated after adequate education and training. (Level 3) (Soucie et al., 2001; Teitel et al., 2004)

An implanted venous access device (Port-A-Cath) can make injections much easier and may be required for administering prophylaxis in younger children. (Level 2) (Neunert et al., 2008; Valentino et al., 2004)

However, the risks of surgery, local infection, and thrombosis associated with such devices need to be weighed against the advantages of starting intensive prophylaxis early. (Level 2) (Ljung, 2007; Ragni, Journeycake, & Brambilla, 2008)

### *Monitoring Health Status and Outcome*

Regular standardized evaluation at least every 12 months allows longitudinal assessment for individual patients and can identify new or potential problems in their early stages so that treatment plans can be modified. (Level 3) (de Moerloose et al., 2012; Feldman et al., 2006; Su et al., 2007)

### *Pain Management*

#### *Pain Due to Chronic Hemophilic Arthropathy*

Treatment includes functional training, adaptations, and adequate analgesia as suggested in Table 1-5 in the original guideline document. (Level 2) (Gomis et al., 2009; Vallejo et al., 2010)

Cyclooxygenase-2 (COX-2) inhibitors have a greater role in this situation. (Level 2) (Ratray, Nugent, & Young, 2006; Tsoukas et al., 2006)

Other non-steroidal anti-inflammatory drugs (NSAIDs) should be avoided. (Level 2) (Eyster et al., 2007)

When pain is disabling, orthopedic surgery may be indicated. (Level 5) (Rodriguez-Merchan, 2010)

#### Surgery and Invasive Procedures

A hemophilia patient requiring surgery is best managed at or in consultation with a comprehensive hemophilia treatment centre. (Level 3) (Batorova & Martinowitz, 2000; Hermans, et al., 2009)

Pre-operative assessment should include inhibitor screening and inhibitor assay, particularly if the recovery of the replaced factor is significantly less than expected. (Level 4) (Mathews et al., 2005; Teitel, et al., 2009)

Patients with mild hemophilia A, as well as patients receiving intensive factor replacement for the first time, are at particular risk of inhibitor development and should be re-screened 4–12 weeks post-operatively. (Level 4) (Kempton et al., 2010)

#### Dental Care and Management

Treatment can be safely carried out under local anesthesia using the full range of techniques available to dental surgeons. Infiltration, intra-papillary, and intra-ligamentary injections are often done under factor cover (20%-40%) though it may be possible for those with adequate experience to administer these injections without it. (Level 4) (Frachon et al., 2005; Hewson et al., 2011)

Dental extraction or surgical procedures carried out within the oral cavity should be done with a plan for hemostasis management, in consultation with the hematologist. (Level 3) (Hermans et al., 2009)

Tranexamic acid or epsilon aminocaproic acid (EACA) is often used after dental procedures to reduce the need for replacement therapy. (Level 4) (Coetzee, 2007; Franchini et al., 2005)

#### Special Management Issues

##### Carriers

Immediate female relatives (mother, sisters, and daughters) of a person with hemophilia should have their clotting factor level checked, especially prior to any invasive intervention, childbirth, or if any symptoms occur. (Level 3) (Plug et al., 2006; Ljung & Tedgård, 2003)

##### Genetic Testing/Counselling and Prenatal Diagnosis

Where available and possible, genetic testing for carrier status should be offered to at-risk female family members of people with hemophilia to facilitate genetic counselling, and if desired by the family, prenatal diagnosis. (Level 4) (Dunn et al., 2008)

Chorionic villus sampling (CVS), or biopsy, is the main method of prenatal diagnosis and is best done between 9 and 14 weeks of gestation. Biopsy carried out earlier may be associated with increased complications including fetal limb abnormalities. (Level 1) (Evans & Andriole, 2008; Jauniaux, Pahal, & Rodeck, 2000; Tabor & Alfirevic, 2010; Wapner, 2005)

All invasive methods used for prenatal diagnosis may cause foeto-maternal hemorrhage. Anti-D immunoglobulin should be given if the mother is RhD negative. (Level 3) (Katiyar et al., 2007)

##### Delivery of Infants with Known or Suspected Hemophilia

FVIII levels usually rise into the normal range during the second and third trimesters and should therefore be measured in carriers during the third trimester of pregnancy to inform decisions for factor coverage during delivery. (Level 3) (Chi et al., 2008)

In carriers with significantly low factor levels (<50 IU/dl), clotting factor replacement is necessary for surgical or invasive procedures including delivery. (Level 3) (Chi et al., 2008)

Delivery of infants with known or suspected hemophilia should be atraumatic, regardless of whether it is vaginal or cesarean, to decrease the risk of bleeding. (Level 3) (Chi et al., 2008)

##### Vaccinations

Persons with bleeding disorders should be vaccinated, but should preferably receive the vaccine subcutaneously rather than intramuscularly or intradermally, unless covered by infusion of clotting factor concentrates. (Level 4) (Kulkarni & Lusher, 2001)

Immunization to hepatitis A and B is important for all persons with hemophilia. These immunizations may not be as effective in those with human immunodeficiency virus (HIV) infection. (Level 4) (Miller et al., 1989; Steele et al., 2009)

#### Ageing Hemophilia Patients

##### *Diabetes Mellitus*

If treatment with insulin is indicated, subcutaneous injections can be administered without bleeding complications. (Level 5) (Mauser-Bunschoten, Fransen Van De Putte, & Schutgens, 2009)

##### *Cardiovascular Disease*

For acute coronary syndromes requiring percutaneous cardiac intervention (PCI):

- Adequate correction with clotting factor concentrates before PCI and until 48 hours after PCI is required. (Level 4) (Schutgens et al., 2009; Mannucci et al., 2009; Coppola, Tagliaferri, & Franchini, 2010)
- Radial artery access site, if technically possible, is preferred over femoral, in order to minimize retroperitoneal or groin bleeds. (Level 4) (Schutgens et al., 2009; Mannucci et al., 2009; Coppola, Tagliaferri, & Franchini, 2010)

#### Laboratory Diagnosis

Knowledge and Expertise in Coagulation Laboratory Testing

##### *Technical Aspects*

##### Inhibitor Testing

The Nijmegen modification of the FVIII inhibitor assay offers improved specificity and sensitivity over the original Bethesda assay. (Level 1) (Meijer & Verbruggen, 2009; Verbruggen, van Heerde, & Laros-van Gorkom, 2009)

##### Hemostatic Agents

##### Clotting Factor Concentrates

The World Federation of Hemophilia (WFH) strongly recommends the use of viral-inactivated plasma-derived or recombinant concentrates in preference to cryoprecipitate or fresh frozen plasma for the treatment of hemophilia and other inherited bleeding disorders. (Level 5) (Evatt, et al., 1999; Farrugia, 2008)

##### *Product Selection*

##### Purity

For treatment of factor IX (FIX) deficiency, a product containing only FIX is more appropriate than prothrombin complex concentrates, which also contain other clotting factors such as factors II, VII, and X, some of which may become activated during manufacture. Products containing activated clotting factors may predispose to thromboembolism. (Level 2) (Kim et al., 1992; Lippi & Franchini, 2008)

##### *FVIII Concentrates*

##### Dosage/Administration

In the absence of an inhibitor, each unit of FVIII per kilogram of body weight infused intravenously will raise the plasma FVIII level approximately 2 IU/dl. (Level 4) (Björkman & Berntorp, 2001)

The patient's factor level should be measured 15 minutes after the infusion to verify the calculated dose. (Level 4) (Björkman & Berntorp, 2001)

FVIII should be infused by slow intravenous (IV) injection at a rate not to exceed 3 ml per minute in adults and 100 units per minute in young children, or as specified in the product information leaflet. (Level 5) (Hemophilia of Georgia, 2012)

Continuous infusion avoids peaks and troughs and is considered by some to be advantageous and more convenient. However, patients must be monitored frequently for pump failure. (Level 3) (Batorova & Martinowitz, 2000; Martinowitz et al., 2009)

## *FIX Concentrates*

Whenever possible, the use of pure FIX concentrates is preferable for the treatment of hemophilia B as opposed to prothrombin complex concentrates (PCC) (Level 2) (Kim et al., 1992; Lippi & Franchini, 2008), particularly in the following instances:

- Surgery
- Liver disease
- Prolonged therapy at high doses
- Previous thrombosis or known thrombotic tendency
- Concomitant use of drugs known to have thrombogenic potential, including antifibrinolytic agents

### Dosage/Administration

In absence of an inhibitor, each unit of FIX per kilogram of body weight infused intravenously will raise the plasma FIX level approximately 1 IU/dl. (Level 4) (Björkman & Berntorp, 2001)

The patient's FIX level should be measured approximately 15 minutes after infusion to verify calculated doses. (Level 4) (Björkman & Berntorp, 2001)

FIX concentrates should be infused by slow intravenous injection at a rate not to exceed a volume of 3 ml per minute in adults and 100 units per minute in young children, or as recommended in the product information leaflet. (Level 5) (Hemophilia of Georgia, 2012)

If used, PCCs should generally be infused at half this rate. Consult the product information leaflet for instructions. (Level 2) (Ruiz-Sáez et al., 2005)

### Other Plasma Products

The WFH supports the use of coagulation factor concentrates in preference to cryoprecipitate or fresh frozen plasma (FFP) due to concerns about their quality and safety. However, the WFH recognizes the reality that they are still widely used in countries around the world where it is the only available or affordable treatment option. (Level 5) (Evatt et al., 1999; Farrugia, 2008)

### *Fresh Frozen Plasma (FFP)*

Cryoprecipitate is preferable to FFP for the treatment of hemophilia A. (Level 4) (Stanworth, 2007)

Due to concerns about the safety and quality of FFP, its use is not recommended, if avoidable (Level 4) (Kasper, 2005). However, as FFP and cryo-poor plasma contain FIX, they can be used for the treatment of hemophilia B in countries unable to afford plasma-derived FIX concentrates.

### Dosage/Administration

An acceptable starting dose is 15–20 ml/kg. (Level 4) (Stanworth, 2007)

### *Cryoprecipitate*

Due to concerns about the safety and quality of cryoprecipitate, its use in the treatment of congenital bleeding disorders is not recommended and can only be justified in situations where clotting factor concentrates are not available. (Level 4) (Evatt et al., 1999; Stanworth, 2007; Chuansumrit et al., 1999)

### Other Pharmacological Options

#### *Desmopressin (DDAVP)*

DDAVP may be the treatment of choice for patients with mild or moderate hemophilia A when FVIII can be raised to an appropriate therapeutic level because it avoids the expense and potential hazards of using a clotting factor concentrate. (Level 3) (Mannucci, 1997; Franchini et al., 2005)

Each patient's response should be tested prior to therapeutic use, as there are significant differences between individuals. The response to intranasal desmopressin is more variable and therefore less predictable. (Level 3) (Mannucci, 1997; Franchini et al., 2005)

DDAVP is particularly useful in the treatment or prevention of bleeding in carriers of hemophilia. (Level 3) (Leissinger, et al., 2001)

Although DDAVP is not licensed for use in pregnancy, there is evidence that it can be safely used during delivery and in the post-partum period in an otherwise normal pregnancy. Its use should be avoided in pre-eclampsia and eclampsia because of the already high levels of von Willebrand

factor (VWF). (Level 3) (Mannucci, 2005; Trigg et al., 2012)

#### Dosage/Administration

A single dose of 0.3 µg/kg body weight, either by intravenous or subcutaneous route, can be expected to boost the level of FVIII three- to six-fold. (Level 4) (Mannucci, 1997; Castaman, 2008)

Closely spaced repetitive use of DDAVP over several days may result in decreased response (tachyphylaxis). Factor concentrates may be needed when higher factor levels are required for a prolonged period. (Level 3) (Mannucci, Bettega & Cattaneo, 1992)

A single metered intranasal spray of 1.5 mg/ml in each nostril is appropriate for an adult. For an individual with a bodyweight of less than 40 kg, a single dose in one nostril is sufficient. (Level 4) (Khair et al., 2007; Rose & Aledort, 1991)

As a result of its antidiuretic activity, water retention and hyponatremia can be a problem. When repeated doses are given, the plasma osmolality or sodium concentration should be measured. (Level 4) (Mannucci, 1997; Sica & Gehr, 2006)

Due to water retention, DDAVP should be used with caution in young children and is contraindicated in children under two years of age who are at particular risk of seizures secondary to cerebral edema due to water retention. (Level 4) (Das, Carcao, & Hitzler, 2005; Smith et al., 1989)

There are case reports of thrombosis (including myocardial infarction) after infusion of DDAVP. It should be used with caution in patients with a history, or who are at risk, of cardiovascular disease. (Level 4) (Castaman, 2008)

#### *Tranexamic Acid*

Regular treatment with tranexamic acid alone is of no value in the prevention of hemarthroses in hemophilia. (Level 4) (Mannucci, 1998)

It is valuable, however, in controlling bleeding from skin and mucosal surfaces (e.g., oral bleeding, epistaxis, menorrhagia). (Level 2) (Coetzee, 2007; Frachon et al., 2005; Kouides et al., 2009)

Tranexamic acid is particularly valuable in the setting of dental surgery and may be used to control oral bleeding associated with eruption or shedding of teeth. (Level 4) (Frachon et al., 2005; Franchini, Zaffanello, & Lippi, 2010)

#### Dosage/Administration

Tranexamic acid may be given alone or together with standard doses of coagulation factor concentrates. (Level 4) (Hvas et al., 2007)

Tranexamic acid should *not* be given to patients with FIX deficiency receiving prothrombin complex concentrates, as this will exacerbate the risk of thromboembolism. (Level 5) (Luu & Ewenstein, 2004)

If treatment with both agents is deemed necessary, it is recommended that at least 12 hours elapse between the last dose of activated prothrombin complex concentrates (APCC) and the administration of tranexamic acid. (Level 5) (Luu & Ewenstein, 2004)

In contrast, thromboembolism is less likely when tranexamic acid is used in combination with recombinant factor VIIa (rFVIIa) to enhance hemostasis. (Level 4) (Giangrande et al., 2009)

#### Treatment of Specific Hemorrhages

##### Joint Hemorrhage (Hemarthrosis)

Administer the appropriate dose of factor concentrate to raise the patient's factor level suitably (refer to Tables 7-1 and 7-2 in the original guideline document). (Level 2) (Aronstam et al., 1980; Aronstam et al., 1983; Hermans et al., 2011; Mathews et al., 2005)

Instruct the patient to avoid weight-bearing, apply compression, and elevate the affected joint. (Level 3) (Hermans et al., 2011)

If bleeding does not stop, a second infusion may be required. If so, repeat half the initial loading dose in 12 hours (hemophilia A) or 24 hours (hemophilia B). (Level 3) (Hermans et al., 2011)

Rehabilitation must be stressed as an active part of the management of acute joint bleeding episodes. (Level 2) (Hermans et al., 2011; Gomis et al., 2009; Mulder, 2006)

##### *Arthrocentesis*

Arthrocentesis (removal of blood from a joint) may be considered in the following situations:

- A bleeding, tense, and painful joint which shows no improvement 24 hours after conservative treatment
- Joint pain that cannot be alleviated
- Evidence of neurovascular compromise of the limb
- Unusual increase in local or systemic temperature and other evidence of infection (septic arthritis) (Level 3) (Hermans et al., 2011; Ingram, Mathews, & Bennett, 1972; Rodriguez-Merchan, 2012)

When necessary, arthrocentesis should be performed under factor levels of at least 30–50 IU/dl for 48–72 hours. Arthrocentesis should not be done in circumstances where such factor replacement is not available. In the presence of inhibitors, other appropriate hemostatic agents should be used for the procedure, as needed. (Level 3) (Hermans et al., 2011)

#### Muscle Hemorrhage

Raise the patient's factor level as soon as possible, ideally when the patient recognizes the first signs of discomfort or after trauma. If there is neurovascular compromise, maintain the levels for five to seven days or longer, as symptoms indicate (refer to Tables 7-1 and 7-2 in the original guideline document). (Level 3) (Aronstam et al., 1983; Beyer, Ingerslev, & Sørensen, 2010; Railton & Aronstam, 1987)

Repeat infusions are often required for two to three days or much longer in case of bleeds at critical sites causing compartment syndromes and if extensive rehabilitation is required. (Level 5) (Rodriguez-Merchan, 2010; Singleton, Kruse-Jarres, & Leissing, 2010)

The patient should be monitored continuously for neurovascular compromise; fasciotomy may be required in some such cases. (Level 5) (Linás et al., 2010; Rodriguez-Merchan, 2008)

Physiotherapy should begin as soon as pain subsides and should be progressed gradually to restore full muscle length, strength, and function. (Level 4) (Beyer, Ingerslev, & Sørensen, 2010; Blamey et al., 2010)

#### Iliopsoas Hemorrhage

Immediately raise the patient's factor level. Maintain the levels for five to seven days or longer, as symptoms indicate (refer to Tables 7-1 and 7-2 in the original guideline document). (Level 4) (Ashrani et al., 2003; Balkan, Kavakli, & Karapinar, 2005; Fernandez-Palazzi et al., 1996)

Hospitalize the patient for observation and control of pain. Maintain *strict* bed rest. Ambulation with crutches is *not* permitted, as ambulation requires contraction of the muscle. (Level 4) (Ashrani et al., 2003; Balkan, Kavakli, & Karapinar, 2005; Fernandez-Palazzi et al., 1996)

It is useful to confirm the diagnosis and monitor recovery with an imaging study (ultrasonography, computed tomography [CT] scan, or magnetic resonance imaging [MRI]). (Level 4) (Ashrani et al., 2003; Balkan, Kavakli, & Karapinar, 2005; Fernandez-Palazzi et al., 1996)

Limit the patient's activity until pain resolves and hip extension improves. A carefully supervised program of physiotherapy is key to restoring full activity and function and preventing re-bleeding. Restoration of complete hip extension before returning to full activity is recommended. (Level 4) (Ashrani et al., 2003; Balkan, Kavakli, & Karapinar, 2005; Fernandez-Palazzi et al., 1996)

#### Central Nervous System Hemorrhage/Head Trauma

*Immediately* raise the patient's factor level when significant trauma or early symptoms occur. Further doses will depend on imaging results. Maintain factor level until etiology is defined. If a bleed is confirmed, maintain the appropriate factor level for 10-14 days (refer to Tables 7-1 and 7-2 in the original guideline document). (Level 4) (Ljung, 2008; Nakar, Cooper, & DiMichele, 2010)

Intracranial hemorrhage may be an indication for prolonged secondary prophylaxis (three to six months), especially where a relatively high risk of recurrence has been observed (e.g., in the presence of HIV infection). (Level 3) (Ljung, 2008; Patiroglu et al., 2011; Zanon et al., 2012)

Immediate medical evaluation and hospitalization is required. A CT scan or MRI of the brain should be performed. Neurological consultation should be sought early. (Level 4) (Traivaree et al., 2007; Witmer et al., 2009)

#### Throat and Neck Hemorrhage

*Immediately* raise the patient's factor level when significant trauma or symptoms occur. Maintain the factor levels until symptoms resolve (refer to Tables 7-1 and 7-2 in the original guideline document). (Level 4) (Singleton, Kruse-Jarres, & Leissing, 2010; Bush & Roy, 1995; Guthrie Jr & Sacra, 1980)

Hospitalization and evaluation by a specialist is essential. (Level 5) (Singleton, Kruse-Jarres, & Leissing, 2010)

#### Acute Gastrointestinal Hemorrhage

*Immediately* raise the patient's factor levels. Maintain the factor level until hemorrhage has stopped and etiology is defined (refer to Tables 7-1 and 7-2 in the original guideline document). (Level 4) (Kouides & Fogarty, 2010; Mittal et al., 1985)

#### Acute Abdominal Hemorrhage

*Immediately* raise the patient's factor levels. Maintain the factor levels (refer to Tables 7-1 and 7-2 in the original guideline document) until the etiology can be defined, then treat appropriately in consultation with a specialist. (Level 4) (Singleton, Kruse-Jarres, & Leissing, 2010; Bush & Roy, 1995; Guthrie Jr & Sacra, 1980)

#### Ophthalmic Hemorrhage

*Immediately* raise the patient's factor level. Maintain the factor level as indicated (refer to Tables 7-1 and 7-2 in the original guideline document). (Level 4) (Singleton, Kruse-Jarres, & Leissing, 2010; Bush & Roy, 1995; Guthrie Jr & Sacra, 1980)

#### Renal Hemorrhage

Treat painless hematuria with complete bed rest and vigorous hydration (3 litres/m<sup>2</sup> body surface area) for 48 hours. Avoid DDAVP when hydrating intensively. (Level 4) (Quon & Konkle, 2010)

Raise the patient's factor levels (refer to Tables 7-1 and 7-2 in the original guideline document) if there is pain or persistent gross hematuria and watch for clots and urinary obstruction. (Level 4) (Quon & Konkle, 2010; Ghosh, Jijina, & Mohanty, 2003)

Do not use antifibrinolytic agents. (Level 4) (Quon & Konkle, 2010)

#### Oral Hemorrhage

Antifibrinolytic agents should not be used systemically in patients with FIX deficiency that are being treated with large doses of prothrombin complex concentrates or in patients with inhibitors being treated with APCC. (Level 4) (Kane et al., 1988; Mannucci, 1998)

Oral EACA or tranexamic acid should be used if appropriate. (Level 4) (Franchini et al., 2005; Vinall & Stassen, 2008)

#### Lacerations and Abrasions

For deep lacerations, raise the factor level (refer to Tables 7-1 and 7-2 in the original guideline document), and then suture. (Level 4) (Singleton, Kruse-Jarres, & Leissing, 2010; Bush & Roy, 1995; Guthrie Jr & Sacra, 1980)

### Complications of Hemophilia

#### Musculoskeletal Complications

##### *Synovitis*

The goal of treatment is to deactivate the synovium as quickly as possible and preserve joint function (Level 5) (Rodriguez-Merchan, 2012; Seuser, Berdel, & Oldenburg, 2007). Options include:

- Factor concentrate replacement, ideally given with the frequency and at dose levels sufficient to prevent recurrent bleeding (Level 2) (Aronstam et al., 1976; Feldman et al., 2006; Gringeri et al., 2011; Manco-Johnson et al., 2007)
- Physiotherapy (Level 2) (Blamey et al., 2010; Gomis et al., 2009)
- A course of NSAIDs (COX-2 inhibitors), which may reduce inflammation (Level 2) (Rattray, Nugent, & Young, 2006; Tsoukas et al., 2006)

##### *Synovectomy*

Synovectomy should be considered if chronic synovitis persists with frequent recurrent bleeding not controlled by other means. Options for synovectomy include chemical or radioisotopic synoviorthesis, and arthroscopic or open surgical synovectomy. (Level 4) (Llinás, 2008; Yoon et al., 2005)

Radioisotopic synovectomy using a pure beta emitter (phosphorus-32 or yttrium-90) is highly effective, has few side effects, and can be accomplished in an out-patient setting. (Level 4) (Thomas et al., 2011; van Kasteren et al., 1993)

#### *Chronic Hemophilic Arthropathy*



Pain should be controlled with appropriate analgesics. Certain COX-2 inhibitors may be used to relieve arthritic pain (see 'Pain Management', above). (Level 2) (Rattray, Nugent, & Young, 2006; Tsoukas et al., 2006)

Supervised physiotherapy aiming to preserve muscle strength and functional ability is a very important part of management at this stage. Secondary prophylaxis may be necessary if recurrent bleeding occurs as a result of physiotherapy. (Level 2) (Blamey et al., 2010; Gomis et al., 2009)

Adequate resources, including sufficient factor concentrates and post-operative rehabilitation, must be available in order to proceed with any surgical procedure. (Level 3) (Hermans et al., 2009; Lobet et al., 2008; Mathews et al., 2005)

### *Pseudotumours*

Management depends on the site, size, rate of growth, and effect on adjoining structures. Options include factor replacement and monitoring, aspiration, and surgical ablation.

- A six-week course of treatment with factor is recommended, followed by repeat MRI. If the tumour is decreasing, continue with factor and repeat MRI for three cycles. (Level 4) (D'Young, 2009; Rodriguez-Merchan, 1995)
- Aspiration of the pseudotumour followed by injections of fibrin glue, arterial embolization, or radiotherapy may heal some lesions. Surgery may be needed for others. (Level 4) (Alcalay & Deplas, 2002; Espandar, Heidari, & Rodriguez-Merchan, 2009)

### *Fractures*

Treatment of a fracture requires immediate factor concentrate replacement. (Level 4) (Rodriguez-Merchan, 2002; Lee et al., 2007; Mortazavi & Heidari, 2008)

Clotting factor levels should be raised to at least 50% and maintained for three to five days. (Level 4) (Rodriguez-Merchan, 2012; Rodriguez-Merchan, 2002; Lee et al., 2007; Mortazavi & Heidari, 2008)

Circumferential plaster should be avoided; splints are preferred. (Level 4) (Rodriguez-Merchan, 2002)

Prolonged immobilization, which can lead to significant limitation of range of movement in the adjacent joints, should be avoided. (Level 4) (Rodriguez-Merchan, 2002; Lee et al., 2007)

### *Principles of Orthopedic Surgery in Hemophilia*

Performing multiple site elective surgery in a simultaneous or staggered fashion to use clotting factor concentrates judiciously should be considered. (Level 3) (Schild et al., 2009)

Local coagulation enhancers may be used. Fibrin glue is useful to control oozing when operating in extensive surgical fields. (Level 3) (Hermans et al., 2009; Kavakli, 1999; Serban et al., 2009)

Post-operative care in patients with hemophilia requires closer monitoring of pain and often higher doses of analgesics in the immediate post-operative period. (Level 5) (Hermans et al., 2009)

### *Inhibitors*

Confirmation of the presence of an inhibitor and quantification of the titre is performed in the laboratory, preferably using the Nijmegen-modified Bethesda assay (see 'Inhibitor testing', above). (Level 1) (Meijer & Verbruggen, 2009; Verbruggen, van Heerde, & Laros-van Gorkom, 2009)

For children, inhibitors should be screened once every five exposure days until 20 exposure days, every 10 exposure days between 21 and 50 exposure days, and at least two times a year until 150 exposure days. (Level 5) (de Moerloose et al., 2012)

For adults with more than 150 exposure days, apart from a 6-12 monthly review, any failure to respond to adequate factor concentrate replacement therapy in a previously responsive patient is an indication to assess for an inhibitor. (Level 3) (Kempton et al., 2010; Berntorp et al., 2011; Hay et al., 2006; McMillan et al., 1988)

Inhibitor measurement should also be done in all patients who have been intensively treated for more than five days, within four weeks of the last infusion. (Level 4) (Hay et al., 2006; Sharathkumar et al., 2003)

Inhibitors should also be assessed prior to surgery or if recovery assays are not as expected, and when clinical response to treatment of bleeding is sub-optimal in the post-operative period. (Level 2) (Astermark et al., 2010; Hay et al., 2006; Teitel et al., 2009)

### *Management of Bleeding*

Management of bleeding in patients with inhibitors must be in consultation with a centre experienced in their management. (Level 5) (Hay et al., 2006; Colvin et al., 2008)

Choice of treatment product should be based on titre of inhibitor, records of clinical response to product, and site and nature of bleed. (Level 4) (Hay et al., 2006; Teitel et al., 2007)

Patients with a low-responding inhibitor may be treated with specific factor replacement at a much higher dose, if possible, to neutralize the inhibitor with excess factor activity and stop bleeding. (Level 4) (Hay et al., 2006; Teitel et al., 2007)

Patients with a history of a high responding inhibitor but with low titres may be treated similarly in an emergency until an anamnestic response occurs, usually in three to five days, precluding further treatment with concentrates that only contain the missing factor. (Level 4) (Hay et al., 2006; Teitel et al., 2007)

The efficacy of two doses of rFVIIa and one dose of APCC for management of joint bleeding has been shown to be essentially equivalent. (Level 2) (Astermark et al., 2007)

Notably, however, some patients respond better to one agent than the other, highlighting the need to individualize therapy. (Level 2) (Astermark et al., 2007; Berntorp et al., 2006)

#### *Allergic Reactions in Patients with Hemophilia B*

Newly diagnosed hemophilia B patients, particularly those with a family history and/or with genetic defects predisposed to inhibitor development, should be treated in a clinic or hospital setting capable of treating severe allergic reactions during the initial 10-20 treatments with FIX concentrates. Reactions can occur later but may be less severe. (Level 4) (Chitlur et al., 2009; Recht et al., 2011)

#### *Immune Tolerance Induction (ITI)*

In patients with severe hemophilia A, eradication of inhibitors is often possible by ITI therapy. (Level 2) (Coppola, Di Minno, & Santagostino, 2010; DiMichele et al., 2007)

Before ITI therapy, high-responding patients should avoid FVIII products to allow inhibitor titres to fall and to avoid persistent anamnestic rise. As noted, some patients may develop an anamnestic response to the inactive FVIII molecules in APCC as well. (Level 2) (DiMichele, 2011)

#### *Patients Switching to New Concentrates*

Patients switching to a new factor concentrate should be monitored for inhibitor development. (Level 2) (Astermark et al., 2010)

#### *Transfusion-transmitted and Other Infection-related Complications*

##### *Principles of Management of HIV Infection in Hemophilia*

As part of the hemovigilance program, all people with hemophilia treated with plasma-derived products that are not adequately virus-inactivated should be tested for HIV at least every 6-12 months and whenever clinically indicated. (Level 4) (Evatt et al., 1999)

The diagnosis, counselling, initiation of treatment, and monitoring of HIV, as well as the treatment of HIV-associated complications in infected people with hemophilia, should be the same as in the non-hemophilic population. (Level 2) (Mannucci et al., 1994; Ragni et al., 1995)

None of the currently available classes of anti-HIV drugs are contraindicated in people with hemophilia. (Level 5) (Humphreys, Chang, & Harris, 2010; Spaulding, Rutherford, & Siegfried, "Tenofvir," 2010; Spaulding, Rutherford, & Siegfried, "Stavudine," 2010)

##### *Principles of Management of Hepatitis C Virus (HCV) Infection in Hemophilia*

The current standard of treatment for HCV is pegylated interferon (PEG-INF) and ribavirin, which give sustained virological response in 61% of people with hemophilia. (Level 1) (Denholm et al., 2009; Franchini et al., 2008; Hartwell et al., 2011; Operskalski & Kovacs, 2011; Posthouwer et al., 2006; Schulze Zur Wiesch et al., 2009)

Where HCV eradication cannot be achieved, regular monitoring (every 6-12 months) for end-stage liver complication is recommended. (Level 3) (Santagostino et al., 2003)

##### *Principles of Management of Hepatitis B Virus (HBV) Infection in Hemophilia*

All people with hemophilia treated with plasma-derived products that are not adequately virus-inactivated should be screened for hepatitis B

antigen and anti-hepatitis B at least every 6-12 months and whenever clinically indicated. (Level 4) (Steele et al., 2009)

Those without HBV immunity should be given the anti-HBV vaccine. Protective seroconversion should be rechecked following vaccination. (Level 4) (Steele et al., 2009; Miller et al., 1989; Pillay et al., 1994)

People with hemophilia who do not seroconvert should be revaccinated with double the hepatitis B vaccine dose. (Level 4) (Steele et al., 2009; Mannucci et al., 1988)

### Plasma Factor Level and Duration of Administration

#### Choice of Factor Replacement Therapy Protocols

Commonly-used dosage for prophylactic factor replacement is 25-40 IU/kg 2-3 times weekly in countries with less resource constraints (see General Care and Management of Hemophilia, above, for details). (Astermark et al., 1999; Blanchette, 2010; Gringeri, et al., 2011)

In situations where there are greater constraints on supply of factor concentrates, prophylaxis may be initiated with lower doses of 10-20 IU/kg 2-3 times per week. (Level 2) (Fischer et al., 2001; Wu et al., 2011)

See Tables 7-1 and 7-2 in the original guideline document for suggested plasma factor peak level and duration of administration, both when there is no significant resource constraint (Table 7-1) and when there is significant resource constraint (Table 7-2).

#### Definitions:

Oxford Centre for Evidence-Based Medicine, 2011 Levels of Evidence (OCEBM-2)

Question	Step 1 (Level 1*)	Step 2 (Level 2*)	Step 3 (Level 3*)	Step 4 (Level 4*)	Step 5 (Level 5*)
<b>How common is the problem?</b>	Local and current random sample surveys (or censuses)	Systematic review of surveys that allow matching to local circumstances**	Local non-random sample**	Case-series**	n/a
<b>Is this diagnostic or monitoring test accurate? (Diagnosis)</b>	Systematic review of cross sectional studies with consistently applied reference standard and blinding	Individual cross sectional studies with consistently applied reference standard and blinding	Non-consecutive studies, or studies without consistently applied reference standards**	Case-control studies, or "poor or non-independent reference standard**	Mechanism-based reasoning
<b>What will happen if therapy is not added? (Prognosis)</b>	Systematic review of inception cohort studies	Inception cohort studies	Cohort study or control arm of randomized trial*	Case-series or case control studies, or poor quality prognostic cohort study**	n/a
<b>Does this intervention help? (Treatment Benefits)</b>	Systematic review of randomized trials or <i>n</i> -of-1 trials	Randomized trial or observational study with dramatic effect	Non-randomized controlled cohort/follow-up study**	Case-series, case-control studies, or historically controlled studies**	Mechanism-based reasoning
<b>What are the COMMON harms? (Treatment Harms)</b>	Systematic review of randomized trials, systematic review of nested case-control studies, <i>n</i> -of-1 trial with the patient you are raising the question about, or observational study with dramatic effect	Individual randomized trial or (exceptionally) observational study with dramatic effect	Non-randomized controlled cohort/follow-up study (post-marketing surveillance) provided there are sufficient numbers to rule out a common harm. (For long-term harms the duration of follow-up must be sufficient.)**	Case-series, case-control, or historically controlled studies**	Mechanism-based reasoning

Question	Step 1 (Level 1*)	Step 2 (Level 2*)	Step 3 (Level 3*)	Step 4 (Level 4*)	Step 5 (Level 5*)
the RARE	Systematic review of randomized trials or <i>n</i> -of-1 trial	Randomized trial or 2*)			
harms? (Treatment Harms)		(exceptionally) observational study with dramatic effect			
Is this (early detection) test worthwhile? (Screening)	Systematic review of randomized trials	Randomized trial	Non-randomized controlled cohort/follow-up study**	Case-series, case-control, or historically controlled studies**	Mechanism-based reasoning

\*Level may be graded down on the basis of study quality, imprecision, indirectness (study Patient-Intervention-Comparison-Outcome [PICO] does not match questions PICO), because of inconsistency between studies, or because the absolute effect size is very small; Level may be graded up if there is a large or very large effect size.

\*\*As always, a systematic review is generally better than an individual study.

OCEBM Levels of Evidence Working Group\*. "The Oxford 2011 Levels of Evidence". Oxford Centre for Evidence-Based Medicine. <http://www.cebm.net/index.aspx?o=5653>

## Clinical Algorithm(s)

None provided

## Scope

## Disease/Condition(s)

Hemophilia

## Other Disease/Condition(s) Addressed

- Diabetes mellitus
- Hypercholesterolemia
- Hypertension
- Obesity
- Osteoporosis

## Guideline Category

Assessment of Therapeutic Effectiveness

Diagnosis

Management

Prevention

Rehabilitation

Screening

Treatment

## Clinical Specialty

Allergy and Immunology

Dentistry

Emergency Medicine

Family Practice

Geriatrics

Hematology

Infectious Diseases

Internal Medicine

Medical Genetics

Neurology

Nursing

Obstetrics and Gynecology

Orthopedic Surgery

Pediatrics

Physical Medicine and Rehabilitation

Preventive Medicine

Psychology

Rheumatology

Surgery

## Intended Users

Advanced Practice Nurses

Allied Health Personnel

Clinical Laboratory Personnel

Dentists

Health Care Providers

Nurses

Occupational Therapists

Patients

Physical Therapists

Physician Assistants

Physicians

Psychologists/Non-physician Behavioral Health Clinicians

Public Health Departments

Social Workers

## Guideline Objective(s)

- To offer practical recommendations on the diagnosis and general management of hemophilia, as well as the prevention and management of complications including musculoskeletal issues, inhibitors, and transfusion-transmitted infections
- To assist healthcare providers seeking to initiate and/or maintain hemophilia care programs, encourage practice harmonization around the world and, where recommendations lack adequate evidence, stimulate appropriate studies

## Target Population

Patients with confirmed or suspected hemophilia

## Interventions and Practices Considered

### Diagnosis

1. Ensuring knowledge and expertise in laboratory coagulation testing (including use of the Nijmegen modification of the factor VIII inhibitor assay)
2. Use of the correct equipment and reagents
3. Quality assurance

### Management/Treatment

1. General care and management:
  - Principles of care (treating acute bleeds as quickly as possible, easily accessible patient identification with information about the bleeding disorder and treatment used, use of desmopressin [DDAVP] for mild-moderate hemophilia)
  - Coordinated comprehensive care team
  - Encouragement of physical fitness and activity while protecting target joints
  - Prophylactic factor replacement therapy
  - Home therapy, including use of implanted venous access device (Port-A-Cath)
  - Regular monitoring of health status and outcome
  - Management of pain due to chronic hemophilic arthropathy (avoiding aspirin and non-steroidal anti-inflammatory drugs [NSAIDs])
  - Performing surgery at or in consultation with a comprehensive hemophilia treatment centre
  - Dental care with plan for hemostatic management (use of tranexamic acid or epsilon aminocaproic acid)
2. Special management issues:
  - Testing clotting factor levels of potential carriers (e.g., female relatives of hemophilia patient)
  - Genetic testing for carrier status of at-risk female family members of people with hemophilia
  - Chorionic villus sampling (CVS) or biopsy for prenatal diagnosis of hemophilia
  - Delivery of infants with known or suspected hemophilia
  - Vaccinations, including immunization to hepatitis A and B
  - Considerations for care of hemophilia patients with comorbid conditions
3. Hemostatic agents: viral-inactivated plasma-derived or recombinant clotting factor concentrates (factor VIII, factor IX), cryoprecipitate, fresh frozen plasma, DDAVP, tranexamic acid, epsilon aminocaproic acid
4. Treatment of specific hemorrhages: joint, muscle, throat and neck, gastrointestinal, acute abdominal, ophthalmic, renal, oral, soft tissue, and central nervous system hemorrhages; head trauma; epistaxis; and lacerations and abrasions
5. Management of complications of hemophilia:
  - Management of musculoskeletal complications
  - Assessment and quantification of inhibitor levels and management of complications related to inhibitors
  - Management of transfusion-transmitted and other infection-related complications including human immunodeficiency virus (HIV), hepatitis B, and hepatitis C
6. Plasma factor level and duration of administration

## 7. Choice of factor replacement therapy protocols

### Major Outcomes Considered

- Efficacy of treatments to prevent or manage bleeding or to prevent treatment adverse effects/complications
- Amount of treatment product required
- Level of function
- Level of pain, dysfunction, or long-term disability
- Frequency of hospital admissions
- Need for replacement therapy
- Sensitivity, specificity, and reliability of diagnostic tests
- Adverse effects of treatments
- Safety of treatments
- Morbidity and mortality
- Quality of life
- Cost-effectiveness

### Methodology

#### Methods Used to Collect/Select the Evidence

Searches of Electronic Databases

#### Description of Methods Used to Collect/Select the Evidence

The Oxford Centre for Evidence-Based Medicine 2011 (OCEBM-2) Level of Evidence table (see the "Rating Scheme for the Strength of the Evidence" field) was used to help find the best evidence in "real time." Through a series of decision-making "steps" to guide each literature search, the OCEBM-2 table is used to conduct a relatively rapid appraisal. The searches start at the highest (strongest) evidence level, i.e., based on systematic reviews, and then move "down" to randomized trials, cohort studies, case control studies/case series, case reports, and, finally, "mechanistic" reasoning.

Evidence for each practice statement in the guideline was gathered by searching Medline, EMBASE (both on Ovid), and the Systematic Review and CENTRAL databases of the Cochrane Library from 2005 onwards. However, because data in the field is thin, the search was subsequently extended to include all the high quality evidence that exists. Databases were searched between mid-January through mid-July 2011.

The query syntax for practice statements is usually based on a combination of natural language and thesaurus controlled terminology – Emtree (for EMBASE) and MeSH (for Medline and the CL databases). For some practice statements the guideline authors used standard Scottish Intercollegiate Guidelines Network (SIGN) hedges and/or McMaster hedges.

#### Number of Source Documents

Not stated

#### Methods Used to Assess the Quality and Strength of the Evidence

Weighting According to a Rating Scheme (Scheme Given)

#### Rating Scheme for the Strength of the Evidence

Oxford Centre for Evidence-Based Medicine, 2011 Levels of Evidence (OCEBM-2)

Question	Step 1 (Level 1*)	Step 2 (Level 2*)	Step 3 (Level 3*)	Step 4 (Level 4*)	Step 5 (Level 5*)
<b>How common is the problem?</b>	Local and current random sample surveys (or censuses)	Systematic review of surveys that allow matching to local circumstances**	Local non-random sample**	Case-series**	n/a
<b>Is this diagnostic or monitoring test accurate? (Diagnosis)</b>	Systematic review of cross sectional studies with consistently applied reference standard and blinding	Individual cross sectional studies with consistently applied reference standard and blinding	Non-consecutive studies, or studies without consistently applied reference standards**	Case-control studies, or "poor or non-independent reference standard**	Mechanism-based reasoning
<b>What will happen if therapy is not added? (Prognosis)</b>	Systematic review of inception cohort studies	Inception cohort studies	Cohort study or control arm of randomized trial*	Case-series or case control studies, or poor quality prognostic cohort study**	n/a
<b>Does this intervention help? (Treatment Benefits)</b>	Systematic review of randomized trials or <i>n</i> -of-1 trials	Randomized trial or observational study with dramatic effect	Non-randomized controlled cohort/follow-up study**	Case-series, case-control studies, or historically controlled studies**	Mechanism-based reasoning
<b>What are the COMMON harms? (Treatment Harms)</b>	Systematic review of randomized trials, systematic review of nested case-control studies, <i>n</i> -of-1 trial with the patient you are raising the question about, or observational study with dramatic effect	Individual randomized trial or (exceptionally) observational study with dramatic effect	Non-randomized controlled cohort/follow-up study (post-marketing surveillance) provided there are sufficient numbers to rule out a common harm. (For long-term harms the duration of follow-up must be sufficient.)**	Case-series, case-control, or historically controlled studies**	Mechanism-based reasoning
<b>What are the RARE harms? (Treatment Harms)</b>	Systematic review of randomized trials or <i>n</i> -of-1 trial	Randomized trial or (exceptionally) observational study with dramatic effect			
<b>Is this (early detection) test worthwhile? (Screening)</b>	Systematic review of randomized trials	Randomized trial	Non-randomized controlled cohort/follow-up study**	Case-series, case-control, or historically controlled studies**	Mechanism-based reasoning

\*Level may be graded down on the basis of study quality, imprecision, indirectness (study Patient-Intervention-Comparison-Outcome [PICO] does not match questions PICO), because of inconsistency between studies, or because the absolute effect size is very small; Level may be graded up if there is a large or very large effect size.

\*\*As always, a systematic review is generally better than an individual study.

OCEBM Levels of Evidence Working Group\*. "The Oxford 2011 Levels of Evidence". Oxford Centre for Evidence-Based Medicine. <http://www.cebm.net/index.aspx?o=5653>

## Methods Used to Analyze the Evidence

Systematic Review



## Description of the Methods Used to Analyze the Evidence

Although the 2011 Oxford Centre for Evidence-Based Medicine (OCEBM-2) table (see the "Rating Scheme for the Strength of the Evidence" field) is intended as a search heuristic rather than a strict hierarchy, normative judgments about strength of evidence are obviously implied. The table can be used for initial assessment of evidence quality, although further appraisal and judgment must be used. The search strategy is designed so that types of evidence further to the left in the table are likely to be stronger than types of evidence further to the right (although there will be exceptions to this rule of thumb). Step 1-5 corresponds to evidence level 1-5 in the OCEBM-2 table. Evidence levels may be graded down on the basis of study quality, imprecision, indirectness, inconsistency between studies, or because the absolute effect size is very small. They may be graded up if there is a large or very large effect size.

## Methods Used to Formulate the Recommendations

Expert Consensus

## Description of Methods Used to Formulate the Recommendations

Many of the recommendations are based on expert opinion. These guidelines also contain recommendations regarding the clinical management of people with hemophilia (practice statements, in bold in the original guideline document). All such statements are supported by the best available evidence in the literature, which were graded as per the 2011 Oxford Centre for Evidence-Based Medicine (see the "Rating Scheme for the Strength of the Evidence" field). Where possible, references for recommendations that fell outside the selection for practice statements were also included. These references have not been graded.

## Rating Scheme for the Strength of the Recommendations

Not applicable

## Cost Analysis

The guideline developers reviewed published cost analyses.

## Method of Guideline Validation

External Peer Review

## Description of Method of Guideline Validation

Given the fact that many recommendations are based on expert opinion, a draft version of these guidelines was circulated to many other opinion leaders involved in hemophilia care outside of the writing group, from around the world. The authors are grateful to those who provided detailed comments.

In addition, the guidelines were peer reviewed upon submission for publication in *Haemophilia*, according to the journal's own policies and practices.

## Evidence Supporting the Recommendations

## References Supporting the Recommendations

---

Alcalay M, Deplas A. Rheumatological management of patients with hemophilia. Part II: Muscle hematomas and pseudotumors. *Joint Bone Spine*. 2002 Dec;69(6):556-9. [15 references] [PubMed](#)

Aronstam A, Arblaster PG, Rainsford SG, Turk P, Slattery M, Alderson MR, Hall DE, Kirk PJ. Prophylaxis in haemophilia: a double-blind controlled trial. *Br J Haematol*. 1976 May;33(1):81-90. [PubMed](#)

Aronstam A, Browne RS, Wassef M, Hamad Z. The clinical features of early bleeding into the muscles of the lower limb in severe haemophiliacs. *J Bone Joint Surg Br*. 1983 Jan;65(1):19-23. [PubMed](#)

Aronstam A, Wassef M, Hamad Z, Cartledge J, McLellan D. A double-blind controlled trial of two dose levels of factor VIII in the treatment of high risk haemarthroses in haemophilia A. *Clin Lab Haematol*. 1983;5(2):157-63. [PubMed](#)

Aronstam A, Wassef M, Choudhury DP, Turk PM, McLellan DS. Double-blind controlled trial of three dosage regimens in treatment of haemarthroses in haemophilia A. *Lancet*. 1980 Jan 26;1(8161):169-71. [PubMed](#)

Ashrani AA, Osip J, Christie B, Key NS. Iliopsoas haemorrhage in patients with bleeding disorders--experience from one centre. *Haemophilia*. 2003 Nov;9(6):721-6. [PubMed](#)

Astermark J, Altisent C, Batorova A, Diniz MJ, Gringeri A, Holme PA, Karafoulidou A, Lopez-Fernandez MF, Reipert BM, Rocino A, Schiavoni M, von Depka M, Windyga J, Fijnvandraat K, European Haemophilia Therapy Standardisation Board. Non-genetic risk factors and the development of inhibitors in haemophilia: a comprehensive review and consensus report. *Haemophilia*. 2010 Sep 1;16(5):747-66. [PubMed](#)

Astermark J, Donfield SM, DiMichele DM, Gringeri A, Gilbert SA, Waters J, Berntorp E, FENOC Study Group. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. *Blood*. 2007 Jan 15;109(2):546-51. [PubMed](#)

Astermark J, Petrini P, Tengborn L, Schulman S, Ljung R, Berntorp E. Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized. *Br J Haematol*. 1999 Jun;105(4):1109-13. [PubMed](#)

Balkan C, Kavakli K, Karapinar D. Iliopsoas haemorrhage in patients with haemophilia: results from one centre. *Haemophilia*. 2005 Sep;11(5):463-7. [PubMed](#)

Batorova A, Martinowitz U. Intermittent injections vs. continuous infusion of factor VIII in haemophilia patients undergoing major surgery. *Br J Haematol*. 2000 Sep;110(3):715-20. [PubMed](#)

Berntorp E, Boulyjenkov V, Brettler D, Chandy M, Jones P, Lee C, Lusher J, Mannucci P, Peak I, Rickard K, et al. Modern treatment of haemophilia. *Bull World Health Organ*. 1995;73(5):691-701. [45 references] [PubMed](#)

Berntorp E, Collins P, D'Oiron R, Ewing N, Gringeri A, Negrier C, Young G. Identifying non-responsive bleeding episodes in patients with haemophilia and inhibitors: a consensus definition. *Haemophilia*. 2011 Jan;17(1):e202-10. [PubMed](#)

Berntorp E, Shapiro A, Astermark J, Blanchette VS, Collins PW, Dinichele D, Escuriola C, Hay CR, Hoots WK, Leissing CA, Negrier C, Oldenburg J, Peerlinck K, Reding MT, Hart C. Inhibitor treatment in haemophilias A and B: summary statement for the 2006 international consensus conference. *Haemophilia*. 2006 Dec;12 Suppl 6:1-7. [PubMed](#)

Beyer R, Ingerslev J, Sorensen B. Current practice in the management of muscle haematomas in patients with severe haemophilia. *Haemophilia*. 2010 Nov;16(6):926-31. [PubMed](#)

Bjorkman S, Berntorp E. Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia. *Clin Pharmacokinet*.

2001;40(11):815-32. [143 references] [PubMed](#)

Blamey G, Forsyth A, Zourikian N, Short L, Jankovic N, De Kleijn P, Flannery T. Comprehensive elements of a physiotherapy exercise programme in haemophilia--a global perspective. *Haemophilia*. 2010 Jul;16(Suppl 5):136-45. [105 references] [PubMed](#)

Blanchette VS. Prophylaxis in the haemophilia population. *Haemophilia*. 2010 Jul;16(Suppl 5):181-8. [46 references] [PubMed](#)

Bush MT, Roy N. Hemophilia emergencies. *J Emerg Nurs*. 1995 Dec;21(6):531-8; quiz 538-40. [6 references] [PubMed](#)

Canadian Hemophilia Standards Group. Canadian comprehensive care standards for hemophilia and other inherited bleeding disorders. [internet]. Toronto (ON): Association of Hemophilia Clinic Directors of Canada (AHCDC); 2007 Jun [accessed 2011 Sep 04].

Castaman G, Mancuso ME, Giacomelli SH, Tosetto A, Santagostino E, Mannucci PM, Rodeghiero F. Molecular and phenotypic determinants of the response to desmopressin in adult patients with mild hemophilia A. *J Thromb Haemost*. 2009 Nov;7(11):1824-31. [PubMed](#)

Castaman G. Desmopressin for the treatment of haemophilia. *Haemophilia*. 2008 Jan;14(Suppl 1):15-20. [21 references] [PubMed](#)

Chi C, Lee CA, Shiltagh N, Khan A, Pollard D, Kadir RA. Pregnancy in carriers of haemophilia. *Haemophilia*. 2008 Jan;14(1):56-64. [PubMed](#)

Chitlur M, Warriar I, Rajpurkar M, Lusher JM. Inhibitors in factor IX deficiency a report of the ISTH-SSC international FIX inhibitor registry (1997-2006). *Haemophilia*. 2009 Sep;15(5):1027-31. [PubMed](#)

Chuansumrit A, Isarangkura P, Chantanakajornfung A, Kuhathong K, Pintadit P, Jitpraphai C, Hathirat P, Nuchprayoon C. The efficacy and safety of lyophilized cryoprecipitate in hemophilia A. *J Med Assoc Thai*. 1999 Nov;82(Suppl 1):S69-73. [PubMed](#)

Coetzee MJ. The use of topical crushed tranexamic acid tablets to control bleeding after dental surgery and from skin ulcers in haemophilia. *Haemophilia*. 2007 Jul;13(4):443-4. [PubMed](#)

Colvin BT, Astermark J, Fischer K, Gringeri A, Lassila R, Schramm W, Thomas A, Ingerslev J, Inter Disciplinary Working Group. European principles of haemophilia care. *Haemophilia*. 2008 Mar;14(2):361-74. [PubMed](#)

Coppola A, Di Minno MN, Santagostino E. Optimizing management of immune tolerance induction in patients with severe haemophilia A and inhibitors: towards evidence-based approaches. *Br J Haematol*. 2010 Sep;150(5):515-28. [PubMed](#)

Coppola A, Tagliaferri A, Franchini M. The management of cardiovascular diseases in patients with hemophilia. *Semin Thromb Hemost*. 2010 Feb;36(1):91-102. [91 references] [PubMed](#)

Das P, Carcao M, Hitzler J. DDAVP-induced hyponatremia in young children. *J Pediatr Hematol Oncol*. 2005 Jun;27(6):330-2. [PubMed](#)

de Moerloose P, Fischer K, Lambert T, Windyga J, Batorova A, Lavigne-Lissalde G, Rocino A, Astermark J, Hermans C. Recommendations for assessment, monitoring and follow-up of patients with haemophilia. *Haemophilia*. 2012 May;18(3):319-25. [PubMed](#)

Denholm JT, Wright EJ, Street A, Sasadeusz JJ. HCV treatment with pegylated interferon and ribavirin in patients with haemophilia and HIV/HCV co-infection. *Haemophilia*. 2009 Mar;15(2):538-43. [PubMed](#)

Di Michele DM. Immune tolerance induction in haemophilia: evidence and the way forward. *J Thromb Haemost*. 2011 Jul;9(Suppl 1):216-25. [PubMed](#)

DiMichele DM, Hoots WK, Pipe SW, Rivard GE, Santagostino E. International workshop on immune tolerance induction: consensus recommendations. *Haemophilia*. 2007 Jul;13(Suppl 1):1-22. [149 references] [PubMed](#)

Dunn NF, Miller R, Griffioen A, Lee CA. Carrier testing in haemophilia A and B: adult carriers' and their partners' experiences and their views on the testing of young females. *Haemophilia*. 2008 May;14(3):584-92. [PubMed](#)

D'Young AI. Conservative physiotherapeutic management of chronic haematomata and haemophilic pseudotumours: case study and comparison to historical management. *Haemophilia*. 2009 Jan;15(1):253-60. [PubMed](#)

Espandar R, Heidari P, Rodriguez-Merchan EC. Management of haemophilic pseudotumours with special emphasis on radiotherapy and arterial embolization. *Haemophilia*. 2009 Mar;15(2):448-57. [47 references] [PubMed](#)

Evans MI, Andriole S. Chorionic villus sampling and amniocentesis in 2008. *Curr Opin Obstet Gynecol*. 2008 Apr;20(2):164-8. [36 references] [PubMed](#)

Evatt BL, Austin H, Leon G, Ruiz-Saez A, De Bosch N. Haemophilia therapy: Assessing the cumulative risk of HIV exposure by cryoprecipitate. *Haemophilia*. 1999;5(5):295-300. [12 references] [PubMed](#)

Evatt BL, Black C, Batorova A, Street A, Srivastava A. Comprehensive care for haemophilia around the world. *Haemophilia*. 2004 Oct;10(Suppl 4):9-13. [19 references] [PubMed](#)

Evatt BL. The natural evolution of haemophilia care: developing and sustaining comprehensive care globally. *Haemophilia*. 2006 Jul;12(Suppl 3):13-21. [46 references] [PubMed](#)

Eyster ME, Asaad SM, Gold BD, Cohn SE, Goedert JJ, Second Multicenter Hemophilia Study Group. Upper gastrointestinal bleeding in haemophiliacs: incidence and relation to use of non-steroidal anti-inflammatory drugs. *Haemophilia*. 2007 May;13(3):279-86. [PubMed](#)

Farrugia A. Guide for the assessment of clotting factor concentrates. 2nd ed. Montreal: World Federation of Hemophilia; 2008.

Feldman BM, Pai M, Rivard GE, Israels S, Poon MC, Demers C, Robinson S, Luke KH, Wu JK, Gill K, Lillicrap D, Babyn P, McLimont M, Blanchette VS, Association of Hemophilia Clinic Directors of Canada Prophylaxis Study Group. Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study. *J Thromb Haemost*. 2006 Jun;4(6):1228-36. [PubMed](#)

Fernandez-Palazzi F, Hernandez SR, De Bosch NB, De Saez AR. Hematomas within the iliopsoas muscles in hemophilic patients: the Latin American experience. *Clin Orthop Relat Res*. 1996 Jul;(328):19-24. [PubMed](#)

Fischer K, van der Bom JG, Mauser-Bunschoten EP, Roosendaal G, Prejs R, de Kleijn P, Grobbee DE, van den Berg M. The effects of postponing prophylactic treatment on long-term outcome in patients with severe hemophilia. *Blood*. 2002 Apr 1;99(7):2337-41. [PubMed](#)

Fischer K, van der Bom JG, Mauser-Bunschoten EP, Roosendaal G, Prejs R, Grobbee DE, van den Berg HM. Changes in treatment strategies for severe haemophilia over the last 3 decades: effects on clotting factor consumption and arthropathy. *Haemophilia*. 2001 Sep;7(5):446-52. [PubMed](#)

Frachon X, Pommereuil M, Berthier AM, Lejeune S, Hourdin-Eude S, Quero J, Meziere X, De Mello G, Garnier J. Management options for dental extraction in hemophiliacs: a study of 55 extractions (2000-2002). *Oral Surg Oral Med Oral Pathol Oral Radiol Endod*. 2005

Franchini M, Mengoli C, Veneri D, Mazzi R, Lippi G, Cruciani M. Treatment of chronic hepatitis C in haemophilic patients with interferon and ribavirin: a meta-analysis. *J Antimicrob Chemother.* 2008 Jun;61(6):1191-200. [51 references] [PubMed](#)

Franchini M, Rossetti G, Tagliaferri A, Pattacini C, Pozzoli D, Lorenz C, Del Dot L, Ugolotti G, Dell'aringa C, Gandini G. Dental procedures in adult patients with hereditary bleeding disorders: 10 years experience in three Italian Hemophilia Centers. *Haemophilia.* 2005 Sep;11(5):504-9. [PubMed](#)

Franchini M, Zaffanello M, Lippi G. The use of desmopressin in mild hemophilia A. *Blood Coagul Fibrinolysis.* 2010 Oct;21(7):615-9. [PubMed](#)

Ghosh K, Jijina F, Mohanty D. Haematuria and urolithiasis in patients with haemophilia. *Eur J Haematol.* 2003 Jun;70(6):410-2. [PubMed](#)

Giangrande PL, Wilde JT, Madan B, Ludlam CA, Tuddenham EG, Goddard NJ, Dolan G, Ingerslev J. Consensus protocol for the use of recombinant activated factor VII [eptacog alfa (activated); NovoSeven] in elective orthopaedic surgery in haemophilic patients with inhibitors. *Haemophilia.* 2009 Mar;15(2):501-8. [PubMed](#)

Gomis M, Querol F, Gallach JE, Gonzalez LM, Aznar JA. Exercise and sport in the treatment of haemophilic patients: a systematic review. *Haemophilia.* 2009 Jan;15(1):43-54. [107 references] [PubMed](#)

Gringeri A, Lundin B, von Mackensen S, Mantovani L, Mannucci PM, ESPRIT Study Group. A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). *J Thromb Haemost.* 2011 Apr;9(4):700-10. [PubMed](#)

Guthrie TH Jr, Sacra JC. Emergency care of the hemophiliac patient. *Ann Emerg Med.* 1980 Sep;9(9):476-9. [PubMed](#)

Hartwell D, Jones J, Baxter L, Shepherd J. Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation. *Health Technol Assess.* 2011 Apr;15(17):i-xii, 1-210. [PubMed](#)

Hay CR, Brown S, Collins PW, Keeling DM, Liesner R. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation. *Br J Haematol.* 2006 Jun;133(6):591-605. [118 references] [PubMed](#)

Hemophilia of Georgia. Protocols for the treatment of hemophilia and von Willebrand disease. [internet]. Atlanta (GA): Hemophilia of Georgia; 2012 [accessed 2012 Jun 06].

Hermans C, Altisent C, Batorova A, Chambost H, De Moerloose P, Karafoulidou A, Klamroth R, Richards M, White B, Dolan G, European Haemophilia Therapy Standardisation Board. Replacement therapy for invasive procedures in patients with haemophilia: literature review, European survey and recommendations. *Haemophilia.* 2009 May;15(3):639-58. [119 references] [PubMed](#)

Hermans C, De Moerloose P, Fischer K, Holstein K, Klamroth R, Lambert T, Lavigne-Lissalde G, Perez R, Richards M, Dolan G, European Haemophilia Therapy Standardisation Board. Management of acute haemarthrosis in haemophilia A without inhibitors: literature review, European survey and recommendations. *Haemophilia.* 2011 May;17(3):383-92. [PubMed](#)

Hewson I, Makhmalbaf P, Street A, McCarthy P, Walsh M. Dental surgery with minimal factor support in the inherited bleeding disorder population at the Alfred Hospital. *Haemophilia.* 2011 Jan;17(1):e185-8. [PubMed](#)

Humphreys EH, Chang LW, Harris J. Antiretroviral regimens for patients with HIV who fail first-line antiretroviral therapy. *Cochrane Database*

Syst Rev. 2010;(6):CD006517. [47 references] [PubMed](#)

Hvas AM, Sorensen HT, Norengaard L, Christiansen K, Ingerslev J, Sorensen B. Tranexamic acid combined with recombinant factor VIII increases clot resistance to accelerated fibrinolysis in severe hemophilia A. *J Thromb Haemost.* 2007 Dec;5(12):2408-14. [PubMed](#)

Ingram GI, Dykes SR, Creese AL, Mellor P, Swan AV, Kaufert JK, Rizza CR, Spooner RJ, Biggs R. Home treatment in haemophilia: clinical, social and economic advantages. *Clin Lab Haematol.* 1979;1(1):13-27. [PubMed](#)

Ingram GI, Mathews JA, Bennett AE. Controlled trial of joint aspiration in acute haemophilic haemarthrosis. *Ann Rheum Dis.* 1972 Sep;31(5):423. [PubMed](#)

Iorio A, Fabbriani G, Marcucci M, Brozzetti M, Filippini P. Bone mineral density in haemophilia patients. A meta-analysis. *Thromb Haemost.* 2010 Mar;103(3):596-603. [PubMed](#)

Jauniaux E, Pahal GS, Rodeck CH. What invasive procedure to use in early pregnancy. *Baillieres Best Pract Res Clin Obstet Gynaecol.* 2000 Aug;14(4):651-62. [77 references] [PubMed](#)

Kane MJ, Silverman LR, Rand JH, Paciucci PA, Holland JF. Myonecrosis as a complication of the use of epsilon amino-caproic acid: a case report and review of the literature. *Am J Med.* 1988 Dec;85(6):861-3. [10 references] [PubMed](#)

Kasper CK, Mannucci PM, Bulyzhenkov V, Brettler DB, Chuansumrit A, Heijnen L, Isarankura P, Kernoff PB, Peake I, Rickard KA, et al. Hemophilia in the 1990s: principles of management and improved access to care. *Semin Thromb Hemost.* 1992 Jan;18(1):1-10. [36 references] [PubMed](#)

Kasper CK. Products for clotting factor replacement in developing countries. *Semin Thromb Hemost.* 2005 Nov;31(5):507-12. [37 references] [PubMed](#)

Katiyar R, Kriplani A, Agarwal N, Bhatla N, Kabra M. Detection of fetomaternal hemorrhage following chorionic villus sampling by Kleihauer Betke test and rise in maternal serum alpha feto protein. *Prenat Diagn.* 2007 Feb;27(2):139-42. [PubMed](#)

Kavakli K, Aydogdu S, Taner M, Duman Y, Balkan C, Karapinar DY, Saydam G, Capaci K, Oktay A. Radioisotope synovectomy with rhenium186 in haemophilic synovitis for elbows, ankles and shoulders. *Haemophilia.* 2008 May;14(3):518-23. [PubMed](#)

Kavakli K. Fibrin glue and clinical impact on haemophilia care. *Haemophilia.* 1999 Nov;5(6):392-6. [30 references] [PubMed](#)

Kempton CL, Soucie JM, Miller CH, Hooper C, Escobar MA, Cohen AJ, Key NS, Thompson AR, Abshire TC. In non-severe hemophilia A the risk of inhibitor after intensive factor treatment is greater in older patients: a case-control study. *J Thromb Haemost.* 2010 Oct;8(10):2224-31. [PubMed](#)

Khair K, Baker K, Mathias M, Burgess C, Liesner R. Intranasal desmopressin (Octim): a safe and efficacious treatment option for children with bleeding disorders. *Haemophilia.* 2007 Sep;13(5):548-51. [PubMed](#)

Kim HC, McMillan CW, White GC, Bergman GE, Horton MW, Saidi P. Purified factor IX using monoclonal immunoaffinity technique: clinical trials in hemophilia B and comparison to prothrombin complex concentrates. *Blood.* 1992 Feb 1;79(3):568-75. [PubMed](#)

Kouides PA, Byams VR, Philipp CS, Stein SF, Heit JA, Lukes AS, Skerrette NI, Dowling NF, Evatt BL, Miller CH, Owens S, Kulkarni R. Multisite management study of menorrhagia with abnormal laboratory haemostasis: a prospective crossover study of intranasal desmopressin and oral tranexamic acid. *Br J Haematol.* 2009 Apr;145(2):212-20. [PubMed](#)

Kouides PA, Fogarty PF. How do we treat: upper gastrointestinal bleeding in adults with haemophilia. *Haemophilia*. 2010 Mar;16(2):360-2. [PubMed](#)

Kulkarni R, Lusher J. Perinatal management of newborns with haemophilia. *Br J Haematol*. 2001 Feb;112(2):264-74. [92 references] [PubMed](#)

Lee VN, Srivastava A, Nithyananth M, Kumar P, Cherian VM, Viswabandya A, Mathews V, George B, Venkatesh K, Nair SC, Chandy M, Sundararaj GD. Fracture neck of femur in haemophilia A - experience from a cohort of 11 patients from a tertiary centre in India. *Haemophilia*. 2007 Jul;13(4):391-4. [PubMed](#)

Leissinger C, Becton D, Cornell C Jr, Cox Gill J. High-dose DDAVP intranasal spray (Stimate) for the prevention and treatment of bleeding in patients with mild haemophilia A, mild or moderate type 1 von Willebrand disease and symptomatic carriers of haemophilia A. *Haemophilia*. 2001 May;7(3):258-66. [PubMed](#)

Lippi G, Franchini M. Pathogenesis of venous thromboembolism: when the cup runneth over. *Semin Thromb Hemost*. 2008 Nov;34(8):747-61. [93 references] [PubMed](#)

Ljung R, Tedgard U. Genetic counseling of hemophilia carriers. *Semin Thromb Hemost*. 2003 Feb;29(1):31-6. [26 references] [PubMed](#)

Ljung R. The risk associated with indwelling catheters in children with haemophilia. *Br J Haematol*. 2007 Sep;138(5):580-6. [58 references] [PubMed](#)

Ljung RC. Intracranial haemorrhage in haemophilia A and B. *Br J Haematol*. 2008 Feb;140(4):378-84. [46 references] [PubMed](#)

Llinas A, Silva M, Pasta G, Luck JV, Asencio JG, Fernandez Palazzi F, Caviglia H, Manco-Johnson M, Seuser A. Controversial subjects in musculoskeletal care of haemophilia: cross fire. *Haemophilia*. 2010 Jul;16(Suppl 5):132-5. [PubMed](#)

Llinas A. The role of synovectomy in the management of a target joint. *Haemophilia*. 2008 Jul;14(Suppl 3):177-80. [PubMed](#)

Lobet S, Pendeville E, Dazell R, Defalque A, Lambert C, Pothen D, Hermans C. The role of physiotherapy after total knee arthroplasty in patients with haemophilia. *Haemophilia*. 2008 Sep;14(5):989-98. [55 references] [PubMed](#)

Luchtman-Jones L, Valentino LA, Manno C, Recombinant Therapy Workshop Participants. Considerations in the evaluation of haemophilia patients for short-term prophylactic therapy: a paediatric and adult case study. *Haemophilia*. 2006 Jan;12(1):82-6. [PubMed](#)

Luu H, Ewenstein B. FEIBA safety profile in multiple modes of clinical and home-therapy application. *Haemophilia*. 2004 Sep;10(Suppl 2):10-6. [30 references] [PubMed](#)

Manco-Johnson MJ, Abshire TC, Shapiro AD, Riske B, Hacker MR, Kilcoyne R, Ingram JD, Manco-Johnson ML, Funk S, Jacobson L, Valentino LA, Hoots WK, Buchanan GR, DiMichele D, Recht M, Brown D, Leissinger C, Bleak S, Cohen A, Mathew P, Matsunaga A, Medeiros D, Nugent D, Thomas GA, Thompson AA, McRedmond K, Soucie JM, Austin H, Evatt BL. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. *N Engl J Med*. 2007 Aug 9;357(6):535-44. [PubMed](#)

Mannucci PM, Bettega D, Cattaneo M. Patterns of development of tachyphylaxis in patients with haemophilia and von Willebrand disease after repeated doses of desmopressin (DDAVP). *Br J Haematol*. 1992 Sep;82(1):87-93. [PubMed](#)

Mannucci PM, Gringeri A, Morfini M, De Biasi R, Tirindelli MC, Tamponi G, Baudo F, Carnelli V, Ciavarella N, Colombo M, et al.

Immunogenicity of a recombinant hepatitis B vaccine in hemophiliacs. *Am J Hematol.* 1988 Dec;29(4):211-4. [PubMed](#)

Mannucci PM, Gringeri A, Savidge G, Gatenby P, Laurian Y, Pabinger-Fasching I, Martinez-Vazquez JM, Hessey EW, Steel HM. Randomized double-blind, placebo-controlled trial of twice-daily zidovudine in asymptomatic haemophiliacs infected with the human immunodeficiency virus type 1. European-Australian Haemophilia Collaborative Study Group. *Br J Haematol.* 1994 Jan;86(1):174-9. [PubMed](#)

Mannucci PM, Schutgens RE, Santagostino E, Mauser-Bunschoten EP. How I treat age-related morbidities in elderly persons with hemophilia. *Blood.* 2009 Dec 17;114(26):5256-63. [71 references] [PubMed](#)

Mannucci PM. Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years. *Blood.* 1997 Oct 1;90(7):2515-21. [66 references] [PubMed](#)

Mannucci PM. Desmopressin (DDAVP) in the treatment of bleeding disorders: the first twenty years. *Haemophilia.* 2000 Jul;6(Suppl 1):60-7. [66 references] [PubMed](#)

Mannucci PM. Hemostatic drugs. *N Engl J Med.* 1998 Jul 23;339(4):245-53. [99 references] [PubMed](#)

Mannucci PM. Use of desmopressin (DDAVP) during early pregnancy in factor VIII-deficient women. *Blood.* 2005 Apr 15;105(8):3382. [PubMed](#)

Martinowitz U, Luboshitz J, Bashari D, Ravid B, Gorina E, Regan L, Stass H, Lubetsky A. Stability, efficacy, and safety of continuously infused sucrose-formulated recombinant factor VIII (rFVIII-FS) during surgery in patients with severe haemophilia. *Haemophilia.* 2009 May;15(3):676-85. [PubMed](#)

Mathews V, Viswabandya A, Baidya S, George B, Nair S, Chandy M, Srivastava A. Surgery for hemophilia in developing countries. *Semin Thromb Hemost.* 2005 Nov;31(5):538-43. [20 references] [PubMed](#)

Mauser-Bunschoten EP, Franssen Van De Putte DE, Schutgens RE. Co-morbidity in the ageing haemophilia patient: the down side of increased life expectancy. *Haemophilia.* 2009 Jul;15(4):853-63. [86 references] [PubMed](#)

McMillan CW, Shapiro SS, Whitehurst D, Hoyer LW, Rao AV, Lazerson J. The natural history of factor VIII:C inhibitors in patients with hemophilia A: a national cooperative study. II. Observations on the initial development of factor VIII:C inhibitors. *Blood.* 1988 Feb;71(2):344-8. [PubMed](#)

Meijer P, Verbruggen B. The between-laboratory variation of factor VIII inhibitor testing: the experience of the external quality assessment program of the ECAT foundation. *Semin Thromb Hemost.* 2009 Nov;35(8):786-93. [PubMed](#)

Miller EJ, Lee CA, Karayiannis P, Holmes S, Thomas HC, Kernoff PB. Immune response of patients with congenital coagulation disorders to hepatitis B vaccine: suboptimal response and human immunodeficiency virus infection. *J Med Virol.* 1989 Jun;28(2):96-100. [PubMed](#)

Mittal R, Spero JA, Lewis JH, Taylor F, Ragni MV, Bontempo FA, Van Thiel DH. Patterns of gastrointestinal hemorrhage in hemophilia. *Gastroenterology.* 1985 Feb;88(2):515-22. [PubMed](#)

Mortazavi SM, Heidari P. Retrograde intramedullary nailing of supracondylar femoral fractures in haemophilic patients. *Haemophilia.* 2008 May;14(3):661-4. [PubMed](#)

Mulder K. Exercises for people with hemophilia. Montreal: World Federation of Hemophilia; 2006.



Nakar C, Cooper DL, DiMichele D. Recombinant activated factor VII safety and efficacy in the treatment of cranial haemorrhage in patients with congenital haemophilia with inhibitors: an analysis of the Hemophilia and Thrombosis Research Society Registry (2004-2008). *Haemophilia*. 2010 Jul 1;16(4):625-31. [PubMed](#)

Neunert CE, Miller KL, Journeycake JM, Buchanan GR. Implantable central venous access device procedures in haemophilia patients without an inhibitor: systematic review of the literature and institutional experience. *Haemophilia*. 2008 Mar;14(2):260-70. [157 references] [PubMed](#)

Operskalski EA, Kovacs A. HIV/HCV co-infection: pathogenesis, clinical complications, treatment, and new therapeutic technologies. *Curr HIV/AIDS Rep*. 2011 Mar;8(1):12-22. [PubMed](#)

Patiroglu T, Ozdemir MA, Unal E, Altuner Torun Y, Coskun A, Menku A, Mutlu FT, Karakukcu M. Intracranial hemorrhage in children with congenital factor deficiencies. *Childs Nerv Syst*. 2011 Nov;27(11):1963-6. [PubMed](#)

Petrini P, Seuser A. Haemophilia care in adolescents--compliance and lifestyle issues. *Haemophilia*. 2009 Jan;15(Suppl 1):15-9. [19 references] [PubMed](#)

Philpott J, Houghton K, Luke A. Physical activity recommendations for children with specific chronic health conditions: Juvenile idiopathic arthritis, hemophilia, asthma and cystic fibrosis. *Paediatr Child Health*. 2010 Apr;15(4):213-25. [PubMed](#)

Pillay D, Pereira C, Sabin C, Powell L, Zuckerman AJ, Lee CA. A long-term follow-up of hepatitis B vaccination in patients with congenital clotting disorders. *Vaccine*. 1994 Aug;12(11):978-83. [PubMed](#)

Plug I, Mauser-Bunschoten EP, Brocker-Vriends AH, van Amstel HK, van der Bom JG, van Diemen-Homan JE, Willemse J, Rosendaal FR. Bleeding in carriers of hemophilia. *Blood*. 2006 Jul 1;108(1):52-6. [PubMed](#)

Posthouwer D, Mauser-Bunschoten EP, Fischer K, Makris M. Treatment of chronic hepatitis C in patients with haemophilia: a review of the literature. *Haemophilia*. 2006 Sep;12(5):473-8. [55 references] [PubMed](#)

Querol F, Aznar JA, Haya S, Cid A. Orthoses in haemophilia. *Haemophilia*. 2002 May;8(3):407-12. [20 references] [PubMed](#)

Quon DV, Konkle BA. How we treat: haematuria in adults with haemophilia. *Haemophilia*. 2010 Jul 1;16(4):683-5. [PubMed](#)

Ragni MV, Amato DA, LoFaro ML, DeGruttola V, Van Der Horst C, Eyster ME, Kessler CM, Gjerset GF, Ho M, Parenti DM, et al. Randomized study of didanosine monotherapy and combination therapy with zidovudine in hemophilic and nonhemophilic subjects with asymptomatic human immunodeficiency virus-1 infection. *AIDS Clinical Trial Groups*. *Blood*. 1995 May 1;85(9):2337-46. [PubMed](#)

Ragni MV, Journeycake JM, Brambilla DJ. Tissue plasminogen activator to prevent central venous access device infections: a systematic review of central venous access catheter thrombosis, infection and thromboprophylaxis. *Haemophilia*. 2008 Jan;14(1):30-8. [66 references] [PubMed](#)

Railton GT, Aronstam A. Early bleeding into upper limb muscles in severe haemophilia. Clinical features and treatment. *J Bone Joint Surg Br*. 1987 Jan;69(1):100-2. [PubMed](#)

Rattray B, Nugent DJ, Young G. Celecoxib in the treatment of haemophilic synovitis, target joints, and pain in adults and children with haemophilia. *Haemophilia*. 2006 Sep;12(5):514-7. [PubMed](#)

Recht M, Pollmann H, Tagliaferri A, Musso R, Janco R, Neuman WR. A retrospective study to describe the incidence of moderate to severe allergic reactions to factor IX in subjects with haemophilia B. *Haemophilia*. 2011 May;17(3):494-9. [PubMed](#)

Rodriguez Merchan EC. The haemophilic pseudotumour. *Int Orthop*. 1995;19(4):255-60. [11 references] [PubMed](#)

Rodriguez-Merchan EC. Aspects of current management: orthopaedic surgery in haemophilia. *Haemophilia*. 2012 Jan;18(1):8-16. [PubMed](#)

Rodriguez-Merchan EC. Bone fractures in the haemophilic patient. *Haemophilia*. 2002 Mar;8(2):104-11. [10 references] [PubMed](#)

Rodriguez-Merchan EC. Musculoskeletal complications of hemophilia. *HSS J*. 2010 Feb;6(1):37-42. [PubMed](#)

Rodriguez-Merchan EC. Orthopedic management in hemophilia: a Spanish outlook. *Semin Hematol*. 2008 Apr;45(2 Suppl 1):S58-63. [15 references] [PubMed](#)

Rose EH, Aledort LM. Nasal spray desmopressin (DDAVP) for mild hemophilia A and von Willebrand disease. *Ann Intern Med*. 1991 Apr 1;114(7):563-8. [PubMed](#)

Ruiz-Saez A, Hong A, Arguello A, Echenagucia M, Boadas A, Fabbrizzi F, Minichilli F, Bosch NB. Pharmacokinetics, thrombogenicity and safety of a double viral inactivated factor IX concentrate compared with a prothrombin complex concentrate. *Haemophilia*. 2005 Nov;11(6):583-8. [PubMed](#)

Santagostino E, Colombo M, Rivi M, Rumi MG, Rocino A, Linari S, Mannucci PM, Study Group of the Association of Italian Hemophilia Centers. A 6-month versus a 12-month surveillance for hepatocellular carcinoma in 559 hemophiliacs infected with the hepatitis C virus. *Blood*. 2003 Jul 1;102(1):78-82. [PubMed](#)

Schild FJ, Mauser-Bunschoten EP, Verbout AJ, Van Rinsum AC, Roosendaal G. Total knee arthroplasty in hemophilic arthropathy: efficiency of clotting factor usage in multijoint procedures. *J Thromb Haemost*. 2009 Oct;7(10):1741-3. [PubMed](#)

Schulze Zur Wiesch J, Pieper D, Stahmer I, Eiermann T, Buggisch P, Lohse A, Hauber J, van Lunzen J. Sustained virological response after early antiviral treatment of acute hepatitis C virus and HIV coinfection. *Clin Infect Dis*. 2009 Aug 1;49(3):466-72. [PubMed](#)

Schutgens RE, Tuinenburg A, Roosendaal G, Guyomi SH, Mauser-Bunschoten EP. Treatment of ischaemic heart disease in haemophilia patients: an institutional guideline. *Haemophilia*. 2009 Jul;15(4):952-8. [PubMed](#)

Serban M, Poenaru D, Pop L, Ionita H, Mihailov MD, Tepeneu N, Badeti R, Lighezan D, Schramm W. Surgery--a challenge in haemophiliacs with inhibitors. *Hamostaseologie*. 2009 Oct;29(Suppl 1):S39-41. [PubMed](#)

Seuser A, Berdel P, Oldenburg J. Rehabilitation of synovitis in patients with haemophilia. *Haemophilia*. 2007 Nov;13(Suppl 3):26-31. [PubMed](#)

Seuser A, Boehm P, Kurme A, Schumpe G, Kurnik K. Orthopaedic issues in sports for persons with haemophilia. *Haemophilia*. 2007 Sep;13(Suppl 2):47-52. [PubMed](#)

Sharathkumar A, Lillierap D, Blanchette VS, Kern M, Leggo J, Stain AM, Brooker L, Carcao MD. Intensive exposure to factor VIII is a risk factor for inhibitor development in mild hemophilia A. *J Thromb Haemost*. 2003 Jun;1(6):1228-36. [50 references] [PubMed](#)

Sica DA, Gehr TW. Desmopressin: safety considerations in patients with chronic renal disease. *Drug Saf*. 2006;29(7):553-6. [PubMed](#)

Singleton T, Kruse-Jarres R, Leissinger C. Emergency department care for patients with hemophilia and von Willebrand disease. *J Emerg*

Med. 2010 Aug;39(2):158-65. [PubMed](#)

Smith TJ, Gill JC, Ambruso DR, Hathaway WE. Hyponatremia and seizures in young children given DDAVP. *Am J Hematol*. 1989 Jul;31(3):199-202. [PubMed](#)

Soucie JM, Nuss R, Evatt B, Abdelhak A, Cowan L, Hill H, Kolakoski M, Wilber N. Mortality among males with hemophilia: relations with source of medical care. The Hemophilia Surveillance System Project Investigators. *Blood*. 2000 Jul 15;96(2):437-42. [PubMed](#)

Soucie JM, Symons J 4th, Evatt B, Brettler D, Huszi H, Linden J, Hemophilia Surveillance System Project Investigators. Home-based factor infusion therapy and hospitalization for bleeding complications among males with haemophilia. *Haemophilia*. 2001 Mar;7(2):198-206. [PubMed](#)

Spaulding A, Rutherford GW, Siegfried N. Stavudine or zidovudine in three-drug combination therapy for initial treatment of HIV infection in antiretroviral-naive individuals. *Cochrane Database Syst Rev*. 2010;(8):CD008651. [64 references] [PubMed](#)

Spaulding A, Rutherford GW, Siegfried N. Tenofovir or zidovudine in three-drug combination therapy with one nucleoside reverse transcriptase inhibitor and one non-nucleoside reverse transcriptase inhibitor for initial treatment of HIV infection in antiretroviral-naive individuals. *Cochrane Database Syst Rev*. 2010;(10):CD008740. [PubMed](#)

Stanworth SJ. The evidence-based use of FFP and cryoprecipitate for abnormalities of coagulation tests and clinical coagulopathy. *Hematology Am Soc Hematol Educ Program*. 2007;:179-86. [54 references] [PubMed](#)

Steele M, Cochrane A, Wakefield C, Stain AM, Ling S, Blanchette V, Gold R, Ford-Jones L. Hepatitis A and B immunization for individuals with inherited bleeding disorders. *Haemophilia*. 2009 Mar;15(2):437-47. [64 references] [PubMed](#)

Su Y, Wong WY, Lail A, Donfield SM, Konzal S, Gomperts E, Hemophilia Growth And Development Study. Long-term major joint outcomes in young adults with haemophilia: interim data from the HGDS. *Haemophilia*. 2007 Jul;13(4):387-90. [PubMed](#)

Tabor A, Alfrevic Z. Update on procedure-related risks for prenatal diagnosis techniques. *Fetal Diagn Ther*. 2010;27(1):1-7. [55 references] [PubMed](#)

Teitel J, Berntorp E, Collins P, D'Oiron R, Ewenstein B, Gomperts E, Goudemand J, Gringeri A, Key N, Leissing C, Monahan P, Young G. A systematic approach to controlling problem bleeds in patients with severe congenital haemophilia A and high-titre inhibitors. *Haemophilia*. 2007 May;13(3):256-63. [PubMed](#)

Teitel JM, Barnard D, Israels S, Lillicrap D, Poon MC, Sek J. Home management of haemophilia. *Haemophilia*. 2004 Mar;10(2):118-33. [198 references] [PubMed](#)

Teitel JM, Carcao M, Lillicrap D, Mulder K, Rivard GE, St-Louis J, Smith F, Walker I, Zourikian N. Orthopaedic surgery in haemophilia patients with inhibitors: a practical guide to haemostatic, surgical and rehabilitative care. *Haemophilia*. 2009 Jan;15(1):227-39. [76 references] [PubMed](#)

Thomas S, Gabriel MB, Assi PE, Barboza M, Perri ML, Land MG, Da Costa ES, Brazilian Hemophilia Centers. Radioactive synovectomy with Yttrium(90) citrate in haemophilic synovitis: Brazilian experience. *Haemophilia*. 2011 Jan;17(1):e211-6. [PubMed](#)

Traivaree C, Blanchette V, Armstrong D, Floros G, Stain AM, Carcao MD. Intracranial bleeding in haemophilia beyond the neonatal period--the role of CT imaging in suspected intracranial bleeding. *Haemophilia*. 2007 Sep;13(5):552-9. [PubMed](#)

Trigg DE, Stergiotou I, Peitsidis P, Kadir RA. A systematic review: The use of desmopressin for treatment and prophylaxis of bleeding disorders in pregnancy. *Haemophilia*. 2012 Jan;18(1):25-33. [PubMed](#)

Tsoukas C, Eyster ME, Shingo S, Mukhopadhyay S, Giallella KM, Curtis SP, Reicin AS, Melian A. Evaluation of the efficacy and safety of etoricoxib in the treatment of hemophilic arthropathy. *Blood*. 2006 Mar 1;107(5):1785-90. [PubMed](#)

Valentino LA, Ewenstein B, Navickis RJ, Wilkes MM. Central venous access devices in haemophilia. *Haemophilia*. 2004 Mar;10(2):134-46. [97 references] [PubMed](#)

Vallejo L, Pardo A, Gomis M, Gallach JE, Perez S, Querol F. Influence of aquatic training on the motor performance of patients with haemophilic arthropathy. *Haemophilia*. 2010 Jan;16(1):155-61. [PubMed](#)

van Kasteren ME, Novakova IR, Boerbooms AM, Lemmens JA. Long term follow up of radiosynovectomy with yttrium-90 silicate in haemophilic haemarthrosis. *Ann Rheum Dis*. 1993 Jul;52(7):548-50. [PubMed](#)

Verbruggen B, van Heerde WL, Laros-van Gorkom BA. Improvements in factor VIII inhibitor detection: From Bethesda to Nijmegen. *Semin Thromb Hemost*. 2009 Nov;35(8):752-9. [43 references] [PubMed](#)

Vinall C, Stassen LF. The dental patient with a congenital bleeding disorder. *J Ir Dent Assoc*. 2008 Feb-Mar;54(1):24-8. [PubMed](#)

Wapner RJ. Invasive prenatal diagnostic techniques. *Semin Perinatol*. 2005 Dec;29(6):401-4. [40 references] [PubMed](#)

Witmer CM, Manno CS, Butler RB, Raffini LJ. The clinical management of hemophilia and head trauma: a survey of current clinical practice among pediatric hematology/oncology physicians. *Pediatr Blood Cancer*. 2009 Sep;53(3):406-10. [PubMed](#)

Wu R, Luke KH, Poon MC, Wu X, Zhang N, Zhao L, Su Y, Zhang J. Low dose secondary prophylaxis reduces joint bleeding in severe and moderate haemophilic children: a pilot study in China. *Haemophilia*. 2011 Jan;17(1):70-4. [PubMed](#)

Yoon KH, Bae DK, Kim HS, Song SJ. Arthroscopic synovectomy in haemophilic arthropathy of the knee. *Int Orthop*. 2005 Oct;29(5):296-300. [PubMed](#)

Zanon E, Iorio A, Rocino A, Artoni A, Santoro R, Tagliaferri A, Coppola A, Castaman G, Mannucci PM, Italian Association of Hemophilia Centers, Barillari G, Dragani A, Gamba G, Giuffrida A, Lapecorella M, Mancuso G, Lucia L, Mazzucconi MG, Messina M, Musso R, De Martis F, Rossetti G, Schinco P, Spiezia L, Valdre L. Intracranial haemorrhage in the Italian population of haemophilia patients with and without inhibitors. *Haemophilia*. 2012 Jan;18(1):39-45. [PubMed](#)

## Type of Evidence Supporting the Recommendations

The type of supporting evidence is identified and graded for each recommendation (see the "Major Recommendations" field).

## Benefits/Harms of Implementing the Guideline Recommendations

### Potential Benefits

Appropriate diagnosis and management of hemophilia

### Potential Harms

- Adverse effects of hemostatic agents:

- The risk of prion-mediated disease through *plasma-derived products* exists. In the absence of a reliable screening test for variant Creutzfeldt-Jakob disease (vCJD), and with no established manufacturing steps to inactivate the vCJD prion, this problem is currently being handled by excluding plasma from all donors perceived to be at risk.
- *Clotting factor concentrates* of lower purity may give rise to allergic reactions.
- *Cryoprecipitate and fresh frozen plasma* are not subjected to viral inactivation procedures (such as heat or solvent/detergent treatment), leading to an increased risk of transmission of viral pathogens, which is significant with repeated infusions. Allergic reactions are more common following infusion of cryoprecipitate than concentrate.
- As a result of its antidiuretic activity, water retention and hyponatremia can be a problem with *desmopressin (DDAVP)*. When repeated doses are given, the plasma osmolality or sodium concentration should be measured. There are case reports of thrombosis (including myocardial infarction) after infusion of DDAVP. It should be used with caution in patients with a history, or who are at risk, of cardiovascular disease.
- Gastrointestinal upset (nausea, vomiting, or diarrhea) may rarely occur as a side effect of *tranexamic acid*, but these symptoms usually resolve if the dosage is reduced. When administered intravenously, it must be infused slowly as rapid injection may result in dizziness and hypotension.
- Gastrointestinal upset is a common complication of epsilon *aminocaproic acid*; reducing the dose often helps. Myopathy is a rare adverse reaction specifically reported in association with aminocaproic acid therapy (but not tranexamic acid), typically occurring after administration of high doses for several weeks. The myopathy is often painful and associated with elevated levels of creatine kinase and even myoglobinuria.
- The risks of surgery, local infection, and thrombosis associated with implanted venous access device (Port-A-Cath) need to be weighed against the advantages of starting intensive prophylaxis early.
- All invasive methods used for prenatal diagnosis may cause feto-maternal hemorrhage. Anti-D immunoglobulin should be given if the mother is RhD negative.

## Contraindications

### Contraindications

- Live virus vaccines (such as oral polio vaccine; measles, mumps, and rubella [MMR]) may be contraindicated in those with human immunodeficiency virus (HIV) infection.
- Due to water retention, desmopressin (DDAVP) should be used with caution in young children and is contraindicated in children under two years of age who are at particular risk of seizures secondary to cerebral edema due to water retention.
- Due to concerns about the safety and quality of fresh frozen plasma (FFP), its use is not recommended, if avoidable.
- The use of tranexamic acid is contraindicated for the treatment of hematuria as its use may prevent dissolution of clots in the ureters, leading to serious obstructive uropathy and potential permanent loss of renal function.
- Similarly, tranexamic acid is contraindicated in the setting of thoracic surgery, where it may result in the development of insoluble hematomas.
- Tranexamic acid should not be given to patients with factor IX (FIX) deficiency receiving prothrombin complex concentrates, as this will exacerbate the risk of thromboembolism.
- Antifibrinolytic agents should not be used systemically in patients with FIX deficiency that are being treated with large doses of prothrombin complex concentrates or in patients with inhibitors being treated with activated prothrombin complex concentrates (APCC).
- Drugs that affect platelet function, particularly acetylsalicylic acid (ASA) and non-steroidal anti-inflammatory drugs (NSAIDs), except certain cyclooxygenase-2 (COX-2) inhibitors, should be avoided in hemophilia patients.

## Qualifying Statements

### Qualifying Statements

- The World Federation of Hemophilia (WFH) does not endorse particular treatment products or manufacturers; any reference to a product name is not an endorsement by the WFH. The WFH does not engage in the practice of medicine and under no circumstances recommends particular treatment for specific individuals. Dose schedules and other treatment regimens are continually revised and new side-effects recognized. These guidelines are intended to help develop basic standards of care for the management of hemophilia and do not replace the

advice of a medical advisor and/or product insert information. Any treatment must be designed according to the needs of the individual and the resources available.

- A question often raised when developing a guideline document such as this is its universal applicability given the diversity of health services and economic systems around the world. The strongly held view of the guideline authors is that the principles of management of hemophilia are the same all over the world. The differences are mainly in the doses of clotting factor concentrates (CFC) used to treat or prevent bleeding, given that the costs of replacement products comprise the major expense of hemophilia care programs. Recognizing this reality, these guidelines continue to include a dual set of dose recommendations for CFC replacement therapy. These are based on published literature and practices in major centres around the world. It should be appreciated, however, that the lower doses recommended may not achieve the best results possible and should serve as the starting point for care to be initiated in resource-limited situations, with the aim of gradually moving towards more optimal doses, based on data and greater availability of CFC.
- The recommendations in these guidelines that are based on low levels of evidence should not be taken as final positions on those subjects. The need for further studies in these fields to create better levels of evidence on which to base practice cannot be overemphasized.

## Implementation of the Guideline

### Description of Implementation Strategy

The World Federation of Hemophilia (WFH) encourages distribution of its materials for educational purposes. These guidelines are available on the *Haemophilia* journal website for free download as well the website of the WFH. The bleeding disorders community has also been informed through more targeted means of communication, which is a continuing process.

The WFH provides support to its national member organizations in their efforts to establish and/or maintain hemophilia care programs, through development programs including the Global Alliance for Progress, the International Hemophilia Treatment Centre fellowship program, the Hemophilia Treatment Centre Twinning Program, and the Advocacy in Action program.

### Implementation Tools

Foreign Language Translations

Patient Resources

Resources

For information about availability, see the *Availability of Companion Documents* and *Patient Resources* fields below.

## Institute of Medicine (IOM) National Healthcare Quality Report Categories

### IOM Care Need

Getting Better

Living with Illness

Staying Healthy

### IOM Domain

Effectiveness

Patient-centeredness

Safety

Timeliness

## Identifying Information and Availability

### Bibliographic Source(s)

Guidelines for the management of hemophilia. 2nd ed. Montreal (Quebec): World Federation of Hemophilia; 2012. 74 p. [324 references]

### Adaptation

Not applicable: The guideline was not adapted from another source.

### Date Released

2012

### Guideline Developer(s)

World Federation of Hemophilia - Nonprofit Organization

### Source(s) of Funding

World Federation of Hemophilia

### Guideline Committee

Treatment Guidelines Working Group

### Composition of Group That Authored the Guideline

*Working Group Members:* Dr. Alok Srivastava (*Chair*), Department of Hematology, Christian Medical College, Vellore, Tamil Nadu, India; Dr. Andrew K. Brewer, Department of Oral Surgery, The Royal Infirmary, Glasgow, Scotland; Dr. Eveline P. Mauser-Bunschoten, Van Creveldklinik and Department of Hematology, University Medical Center Utrecht, Utrecht, the Netherlands; Dr. Nigel S. Key, Department of Medicine, University of North Carolina, Chapel Hill, NC, U.S.A.; Dr. Steve Kitchen, Sheffield Haemophilia and Thrombosis Centre, Royal Hallamshire Hospital, Sheffield, UK; Dr. Adolfo Llinas, Department of Orthopaedics and Traumatology, Fundación Santa Fe University Hospital Fundación, Cosme y Damián and Universidad de los Andes and Universidad del Rosario, Bogotá, Colombia; Dr. Christopher A. Ludlam, Comprehensive Care Haemophilia and Thrombosis Centre, Royal Infirmary, Edinburgh, UK; Dr. Johnny N. Mahlangu, Hemophilia Comprehensive Care Centre, Johannesburg Hospital and Department of Molecular Medicine and Haematology, Faculty of Health Sciences, National Health Laboratory Services and University of the Witwatersrand, Johannesburg, South Africa; Kathy Mulder, Department of Physiotherapy, Child Health, and Manitoba Bleeding Disorders Clinic, Health Sciences Center, Winnipeg, Canada; Dr. Man-Chiu Poon, Departments of Medicine, Pediatrics and Oncology, and Southern Alberta Rare Blood and Bleeding Disorders Comprehensive Care Program, University of Calgary, Foothills Hospital and Calgary Health Region, Alberta, Canada; Dr. Alison Street, Department of Haematology, Alfred Hospital Melbourne, Australia

### Financial Disclosures/Conflicts of Interest

Dr. Srivastava has received competitive peer reviewed grant support from the Bayer Hemophilia Awards Program and also serves on their Grants Review and Awards Committee.

Dr. Key has acted as a paid consultant to Novo Nordisk and has received grant funding from Baxter.

Dr. Kitchen has acted as a paid consultant to Novo Nordisk, Pfizer, and Bayer. Dr. Llinas has lectured for Baxter, Novo Nordisk, Pfizer, and Bayer and has performed clinical trials for Bayer and Baxter.

Dr. Ludlam has received an educational grant from Novo Nordisk, has acted as medical advisor for Ipsen, a consultant for Biogen Idec and Baxter as well as Bayer, from which he has also received funding to attend medical conferences.

Dr. Mauser-Bunschoten has received unrestricted research funding from CSL Behring, is a speaker for Bayer, Sanquin Bloedvoorziening, and Novo Nordisk, and has received funding for postmarketing surveillance by Wyeth, Baxter and Sanquin Bloedvoorziening. She is also the principal investigator for a FIX long-acting product trial sponsored by NovoNordisk.

Dr. Poon has attended advisory board meetings of CSL Behring, Novo Nordisk, Octapharma, and Pfizer. He has attended sponsored meetings on behalf of Baxter and Bayer, is a speaker for Pfizer, and acted as chair of Novo Nordisk's expert panel on Glanzmann's Thrombasthenia registry.

Dr Mahlangu has performed clinical research for Biogen, Bayer and NovoNordisk. He has participated in scientific advisory board meetings and has lectures for Bayer, Amgen and NovoNordisk.

The other authors have no competing interests to declare.

## Guideline Status

This is the current release of the guideline.

This guideline updates a previous version: Guidelines for the management of hemophilia. Montreal (Quebec): World Federation of Hemophilia; 2005. 56 p.

## Guideline Availability

Electronic copies: Available in Portable Document Format (PDF) from the [World Federation of Hemophilia \(WFH\) Web site](#)

Copies can be purchased in Chinese and French from the [WFH Web site](#) .

## Availability of Companion Documents

A compendium of assessment tools: an evaluation of various assessment tools, including the Hemophilia Joint Health Score (HJHS), World Federation of Hemophilia (WFH) Physical Examination Score (Gilbert score), Haemophilia Activities List (HAL), Haemophilia Activities List – Pediatric (PedHAL), and Functional Independence Score in Hemophilia (FISH), as well as the tools themselves, are available from the [World Federation of Hemophilia \(WFH\) Web site](#) .

## Patient Resources

The following is available:

- What is hemophilia? Available from the [World Federation of Hemophilia \(WFH\) Web site](#) .

Please note: This patient information is intended to provide health professionals with information to share with their patients to help them better understand their health and their diagnosed disorders. By providing access to this patient information, it is not the intention of NGC to provide specific medical advice for particular patients. Rather we urge patients and their representatives to review this material and then to consult with a licensed health professional for evaluation of treatment options suitable for them as well as for diagnosis and answers to their personal medical questions. This patient information has been derived and prepared from a guideline for health care professionals included on NGC by the authors or publishers of that original guideline. The patient information is not reviewed by NGC to establish whether or not it accurately reflects the original guideline's content.



## NGC Status

This NGC summary was completed by ECRI Institute on March 11, 2013. The information was verified by the guideline developer on April 12, 2013. This summary was updated by ECRI Institute on September 18, 2015 following the U.S. Food and Drug Administration advisory on non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs).

## Copyright Statement

This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions.

## Disclaimer

### NGC Disclaimer

The National Guideline Clearinghouse<sup>®</sup> (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.

All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.

Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the [NGC Inclusion Criteria](#).

NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding guideline content are directed to contact the guideline developer.